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Abstract
The prevalence of obesity, defined as a body mass index (BMI)> 30, has been
rising on a worldwide scale over recent decades. Obesity and the metabolic
syndrome are associated with health impairments, e.g., insulin resistance and
hypothalamic-pituitary-adrenal (HPA) axis hyperactivity, as well as reduced
quality of life. Therefore, the physiological systems that regulate energy in-
take and body weight are of great interest not only to basic research but also as
possible targets of interventions to improve metabolic control. Several endoge-
nous neuropeptides released in association with metabolic function have been
investigated for their potential to block orexigenic (appetite-stimulating) and
to promote anorexigenic (appetite-suppressing) signaling cascades in the brain
as well as for their insulin-sensitizing and stress-regulating properties. The
present thesis aims at characterizing the role of three of these neuropeptides,
i.e., oxytocin, insulin, and orexin A, in the control of food intake, HPA axis
activity, and, respectively, glucose metabolism in humans. For these investiga-
tions, the intranasal administration paradigm is the method of choice because
it enables neuropeptides to bypass the blood-brain barrier and reach the cen-
tral nervous system quickly, efficiently, and non-invasively while peripheral
uptake is minimized. Three studies were performed in which we investigated
the impact of oxytocin via the intranasal route (24 IU) on eating behavior
and metabolic function in obese men (mean BMI of 32.10) in comparison to
normal-weight men (mean BMI of 22.66; Study I), the influence of intranasal
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insulin administration (160 IU) in elderly (70.0 years) and young subjects
(23.6 years) on early-sleep nadir concentrations of adrenocorticotropin and
cortisol, i.e., indicators of baseline HPA axis activity (Study II), and the acute
glucoregulatory effect of intranasal orexin A administration (500 nmol) during
an oral glucose tolerance test in healthy young men (Study III). In Study I,
intranasal oxytocin exerted an acutely inhibitory impact on food intake that
was enhanced in obese compared with normal-weight men in that hunger- as
well as reward-driven eating was attenuated by oxytocin in obese participants,
whereas normal-weight subjects only showed a reduction in reward-driven
snack intake. HPA axis secretion and the postprandial rise in plasma glu-
cose were blunted by oxytocin in both groups. In Study II, intranasal insulin
reduced cortisol levels during early sleep in elderly but not young partici-
pants, indicating that central nervous insulin can act as an inhibitory signal in
basal HPA axis activity regulation. In particular, insulin may normalize sleep-
associated HPA axis activity in elderly subjects who show relatively increased
nadir values of stress hormones during early sleep. In Study III, intranasal
orexin A attenuated the peak excursion of plasma glucose and lactate levels
and blunted the initial increases in insulin and C-peptide concentrations in
response to a glucose challenge, findings that are in line with respective ani-
mal studies. Taken together, these results indicate that oxytocin, insulin, and
orexin A, in addition to their well-characterized role in other organ systems
and bodily functions, contribute to the regulation of, respectively, feeding
behavior, stress axis activity, and glucose homeostasis in humans. These
results bode well for potential clinical applications of oxytocin, insulin, and
orexin A in the treatment of metabolic disorders.
Zusammenfassung
Die Prävalenz von Adipositas, definiert als Body Mass Index (BMI)> 30, hat
weltweit in den letzten Jahrzehnten kontinuierlich zugenommen. Adipositas
und das Metabolische Syndrom sind mit gesundheitlichen Beeinträchtigun-
gen (z. B. einer Insulinresistenz und überhöhter Hypothalamus-Hypophysen-
Nebennierenrinden-(HHN)-Achsenaktivität) sowie einer verminderten Le-
bensqualität verbunden. Deshalb sind die physiologischen Mechanismen,
die die Energiehomöostase und das Körpergewicht regulieren, nicht nur für
die Grundlagenforschung sondern auch im Rahmen der medikamentösen
Therapieansätze bei Adipositas von großem Interesse. In diesem Zusam-
menhang wurden verschiedene endogene Neuropeptide, die an der meta-
bolischen Regulation beteiligt sind, hinsichtlich ihres Potenzials, orexigene
(appetitsteigernde) Signalkaskaden im Gehirn zu blockieren bzw. anorexige-
ne (appetitmindernde) zu verstärken sowie ihrer insulinsensitivierenden und
stressregulierenden Eigenschaften untersucht. Die vorliegende Arbeit zielt
darauf ab, die Rolle dreier Neuropeptide – Oxytocin, Insulin und Orexin A –
in der Steuerung des Essverhaltens, der HHN-Achsenaktivität und des Gluko-
sestoffwechsels beim Menschen zu charakterisieren. Um dies zu untersuchen,
hat sich die intranasale Applikation als praktikabler Ansatz erwiesen, weil
er die Blut-Hirn-Schranke umgeht und dem Gehirn Neuropeptide schnell,
effektiv und nicht-invasiv zuführen kann, während die periphere Aufnahme
dabei minimiert wird. Es wurden drei Studien durchgeführt, in denen wir
xeinerseits die Auswirkung von intranasal verabreichtem Oxytocin (24 IE) auf
das Essverhalten und den Metabolismus bei adipösen Männern (mittlerer
BMI von 32.10) im Vergleich zu normalgewichtigen männlichen Probanden
(mittlerer BMI von 22.66) untersuchten (Studie I). Des Weiteren wurde der
Einfluss von intranasalem Insulin (160 IE) bei älteren (im Mittel 70.0 Jahre)
und jungen Probanden (im Mittel 23.6 Jahre) auf die frühnächtlichen Nadir-
Konzentrationen von Adrenocorticotropin und Cortisol, welche Indikatoren
der basalen HHN-Achsenaktivität sind (Studie II), sowie die glucoregulatori-
sche Wirkung von intranasal appliziertem Orexin A (500 nmol) während eines
oralen Glukosetoleranztests bei gesunden, jungen Männern untersucht (Stu-
die III). In Studie I wurde die Nahrungsaufnahme insbesondere bei adipösen
im Vergleich zu normalgewichtigen Männern durch die intranasale Gabe von
Oxytocin gehemmt. Adipöse Probanden zeigten eine Reduktion im hunger-
und belohnungsgesteuerten Essverhalten, wobei normalgewichtige Probanden
lediglich eine Reduktion im belohnungsassoziierten Snackverzehr aufwie-
sen. Die Sekretion der HHN-Achse sowie der postprandiale Glukoseanstieg
im Plasma wurden in beiden Gruppen durch Oxytocin gesenkt. In Studie II
senkte intranasal verabreichtes Insulin die frühnächtlichen Cortisolspiegel
bei älteren Probanden, nicht aber bei jungen Studienteilnehmern, was dar-
auf hinweist, dass die zentralnervöse Insulinsignalübertragung die basale
HHN-Achsenaktivität hemmt. Insbesondere kann intranasales Insulin dazu
beitragen, die schlaf-assoziierte Stress-Achsenaktivität bei älteren Proban-
den zu normalisieren, welche erhöhte frühnächtliche Nadir-Konzentrationen
von Stresshormonen aufweisen. In Studie III führte die intranasale Gabe
von Orexin A zu einer Senkung der Glukosespitzen und Laktatspiegel und
schwächte die anfänglichen Insulin- und C-Peptid-Ausschüttungen als Re-
aktion auf die Glukosebelastung ab. Diese Befunde stimmen mit jenen aus
tierexperimentellen Studien überein. Zusammengefasst zeigen die Ergebnisse,
dass Oxytocin, Insulin und Orexin A, neben dem bereits gut untersuchten
Einfluss auf andere Organsysteme und Körperfunktionen, an der Regulati-
on des Essverhaltens, der Stressachsenaktivität und der Glukosehomöostase
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beim Menschen beteiligt sind. Die Ergebnisse können hierbei zur Erkundung
des therapeutischen Potenzials von Oxytocin, Insulin und Orexin A in der
Behandlung von Stoffwechselstörungen beitragen.
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1 | Introduction
1.1 Obesity and metabolic syndrome on the rise
Over the last forty years, obesity and hyperalimentation (overeating) have
become a major public health concern that is being increasingly seen through-
out the world (Finucane et al., 2011) and are strongly associated with health
impairment and reduced quality of life (Taylor et al., 2013). The World Health
Organization (WHO) reported that more than 1.9 billion of the adult popu-
lation worldwide was overweight or obese in 2014, i.e., exhibiting a body
mass index (BMI) > 25kg/m2 (WHO, 2015). In Germany, 55 % of adults
are currently overweight (BMI 25.0 to 29.9 kg/m2), and another 20 % are
obese (BMI > 30kg/m2) (WHO, 2015). The interpretation of BMI gradings
in relation to health risk, i.e., increased mortality and chronic morbidity, is
proposed in Table 1.1.
Obesity independently contributes to a cluster of risk factors that com-
monly appear together and have been termed the ‘metabolic syndrome.’ The
metabolic syndrome found its way into the International Classification of
Diseases (ICD-10; code E88.9), but it is not unambiguously defined. Different
metabolic disturbances including impaired glucose metabolism, dyslipidemia
(a condition characterized by an abnormal amount of blood lipids), high blood
pressure, and visceral obesity are subsumed under the medical term metabolic
syndrome (Alberti et al., 2009), which eventually leads to an increased risk
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Table 1.1 Classification of overweight in adults by the WHO.
Classification BMI Associated health risks
Underweight < 18.5 Low (but risk of other clinical prob-
lems increased)
Normal range 18.5–24.9 Average
Overweight 25.0 or higher
Preobese 25.0–29.9 Increased
Obese class I 30.0–34.9 Moderately increased
Obese class II 35.0–39.9 Severely increased
Obese class III 40.0 or higher Very severely increased
Body mass index (BMI) values are both age- and sex-independent. Note that
BMI may not correspond to the same degree of adiposity in different popu-
lations due, in part, to differences in body proportions. The risks associated
with increasing BMI are continuous and graded and begin at a BMI above
25. However, for calculating the risk of obesity comorbidites, a measure of
fat distribution (body fat, waist circumference or waist-to-hip ratio) must be
consulted in addition to BMI (adapted from WHO, 2000).
of cardiovascular disease and type 2 diabetes mellitus (Kaur, 2014). Accord-
ing to estimates of the International Diabetes Federation (IDF), 8.8 % of the
world’s population suffer from diabetes in 2015; this number is projected to
increase to 10.4 % by 2040 (IDF, 2015).
Associated with obesity, impaired insulin sensitivity or insulin resistance,
respectively, appear as critical factors in the pathophysiology of the metabolic
syndrome (Haffner et al., 1992; Hu et al., 2004). Insulin resistance is defined
as a pathological condition in which cells fail to respond normally to the
insulin-mediated glucose disposal into skeletal muscle and other tissues. As
a consequence, glucose remains in the blood, triggering the need for more
and more insulin (hyperinsulinemia) to be produced in an attempt to process
the glucose (Lebovitz, 2001). Hyperinsulinemia is also involved in obese
hypertension by increasing renal sodium retention (Modan et al., 1985).
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Prolonged chronic (psychosocial) stress is discussed as a further critical
factor in the pathogenesis for metabolic syndrome by perturbation of the
hypothalamic-pituitary-adrenal axis (HPA axis, see section 1.2.2) manifested
in raised basal cortisol and corticotropin-releasing hormone (CRH) levels
(Brunner et al., 2002; Gohil et al., 2001; Kaufman et al., 2007). The gluco-
corticoid hormone cortisol raises blood pressure (Whitworth et al., 1984),
stimulates hepatic gluconeogenesis (generation of glucose) (Argaud et al.,
1996), promotes adipogenesis (adipocyte differentiation) (Hauner et al., 1989),
inhibits insulin-stimulated glucose utilization by adipocytes (Livingston and
Lockwood, 1975), and increases lipolysis or non-esterified fatty oxidation,
which is associated with peripheral insulin resistance (Guillaume-Gentil et al.,
1993). Excessive levels of cortisol over extended periods of time, so called
chronic hypercortisolism, therefore consequently promotes insulin resistance,
hypertension, and visceral obesity (Tsigos and Chrousos, 2002). Thus, HPA
axis dysregulations contribute significantly to the reported risk indication of
obesity to cardiovascular disease and type 2 diabetes (Rosmond and Björntorp,
2000).
Considering the multifactorial pathogenesis of obesity and metabolic syn-
drome, respectively, three major risk domains can be identified: genetics (i.e.,
heredity), lifestyle habits (e.g., eat high-caloric foods) and medical factors
(e.g., psychological issues/stress, age; Marti et al., 2004). The present thesis
focuses on distinct risk determinants covering metabolic as well as behavioral
aspects, i.e., food intake, stress axis regulation, and insulin sensitivity in
particular. Unhealthy diet, chronic stress, and disturbed insulin sensitivity as
pivotal risk determinants in the development of obesity present conventional
therapeutic programmes with huge challenges on the one hand but also appear
to offer a wide range of possibilities for new additional and supportive inter-
ventions on the other. For instance, several endogenous peripheral and central
neuropeptides released in the context of eating have already been investigated
as potential treatments for obesity, e.g., blocking orexigenic peptide signals
such as neuropeptide Y and melanin-concentrating hormone, and are still be-
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ing explored (Boughton and Murphy, 2013). Improving metabolic function by
intranasal administration of neuropeptides involved in metabolic control may
be an innovative approach in the treatment of metabolic ailments (Chapman
et al., 2013; Spetter and Hallschmid, 2015). In the present thesis, the role of
the pancreatic hormone insulin and the hypothalamic neuropeptides oxytocin
and orexin A in food intake, stress axis regulation, and glucose metabolism as
well as their therapeutic potential shall be further elucidated.
1.2 Neuroendocrine regulation of metabolic
function
The hypothalamus is recognized as the main region in the brain regulating
food intake by a complex integration of peripheral and central neuropeptide
signals, such as leptin, insulin, ghrelin, orexins, oxytocin, and through the
sensing of nutrients, such as glucose, amino acids, and fatty acids (Blouet and
Schwartz, 2010; Coll et al., 2007). Besides hypothalamic nuclei regulating
hunger and satiety, several limbic and cortical brain regions regulate energy
intake and are critically involved in the pathophysiology of obesity (Petrovich
et al., 2005). The following sections give a brief and basic overview of the
brain’s role in the control of body weight regulation.
1.2.1 Central nervous regulation of food intake and glucose
metabolism: homeostatic and non-homeostatic path-
ways
Body weight, energy expenditure, and food intake are tightly regulated by
complex homeostatic mechanisms. Besides local paracrine actions and pe-
ripheral endocrine effects mediated through the bloodstream, especially cen-
tral circuits are significantly involved in the control of metabolic processes.
Peripheral, humoral signals indicating information about nutritional status
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interact with several neural signals, e.g., neuropeptides, monoamines, and
endocannabinoids in the brain (Valassi et al., 2008). The main regions and
pathways regulating food consumption are illustrated in Figure 1.1.
Cholecystokinin (CCK), peptide YY3-36 (PYY3-36), glucagon-like peptide-
1 (GLP-1), and ghrelin, are referred to as ‘satiety signals’ generated in the
gastrointestinal tract during food intake. These signals reach the caudal
brainstem nucleus of the solitary tract (NTS) via the vagus nerve, where
they influence meal size. Afferent nerves from NTS project to the arcuate
nucleus (ARC), the primary hypothalamic area involved in the control of
food intake. The ARC, contains two distinct neuropeptidergic pathways with
interconnected but functionally discrete populations of ‘first-order’ neurons.
One group synthesizes the anorexigenic prepropeptide pro-opiomelanocortin
(POMC) and cocaine and amphetamine-regulated transcript (CART). The
precursor polypeptide POMC is cleaved into α-melanocyte-stimulating hor-
mone (α-MSH) which binds to melanocortin-3 and -4 receptors (MC3R and
MC4R) on neurons in other hypothalamic areas and elsewhere in the brain
(Fan et al., 1997). The second group of arcuate neurons co-express the orexi-
genic molecules neuropeptide Y (NPY) and agouti-related peptide (AgRP).
AgRP serves as a non-selective endogenous antagonist of MC3R and MC4R
which thereby reduces the anorexigenic effect of α-MSH (Rossi et al., 1998).
The ARC also receives peripheral information via ‘adiposity signals,’
i.e., leptin and insulin, secreted by white adipose tissue and the pancreas,
respectively. Leptin and insulin circulate in the blood at concentrations pro-
portionate to body-fat mass and enter the brain independently via saturable
mechanisms (Banks et al., 1996; Baura et al., 1993). When these adiposity
signals reach the ARC, a catabolic circuit is activated due to α-MSH sig-
naling which results in an anorexigenic response (decrease in food intake
and meal termination) together with increased energy expenditure (Morton
et al., 2006). In contrast, low levels of adiposity signals in the brain indicating
a need for food and for replenishing energy stores lead to an activation of
an anabolic pathway which enhances food intake (orexigenic response) and
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Figure 1.1 Chief hypothalamic pathways in the regulation of food intake.
(Caption on next page.)
1.2 Neuroendocrine regulation of metabolic function 7
Figure 1.1 (Previous page.) Diagram showing the interrelationship between
orexigenic (black circles) and anorexigenic neuropeptides (white circles) and
their major sites of origin and action. Solid and dotted lines indicate a stimula-
tory and inhibitory effect, respectively. Abbreviations: ARC, arcuate nucleus;
NTS, nucleus of the solitary tract; CCK, cholecystokinin; GLP-1, glucagon-
like peptide-1; PYY3-36, peptide YY3-36; PVN, paraventricular nucleus; LHA,
lateral hypothalamic area; NPY, neuropeptide Y; AgRP, agouti-related peptide;
POMC, pro-opiomelanocortin; CART, cocaine- and amphetamine-regulated
transcript; CRH, corticotropin-releasing hormone; TRH, thyrotropin-releasing
hormone; MCH, melanin-concentrating hormone; VMH, ventromedial nu-
cleus of hypothalamus.
reduces energy expenditure, respectively (Morton et al., 2006). NPY/AgRP
neurons are stimulated by ghrelin (Cowley et al., 2003) and are inhibited by
leptin, insulin, and PYY3-36 (Morton et al., 2006), whereas POMC neurons
are stimulated by circulating concentrations of leptin but inhibited by neigh-
boring NPY/AgRP neurons (Arora and Anubhuti, 2006; Cowley et al., 2001).
Arcuate neurons are also sensitive to local levels of energy-dense nutrients,
including glucose (Levin, 2006), fatty acids (Lam et al., 2005), and some
amino acids (Cota et al., 2006). Low glucose levels activate NPY neurons
(Beck et al., 1990), but inhibit POMC signaling activity (Brady et al., 1990).
Taken together, the POMC-originating tract has an overall catabolic effect,
whereas the NPY/AgRP-originating tract is anabolic.
The ARC is extensively connected with other hypothalamic appetite-
regulating regions in a reciprocal manner, where two nearby target areas,
namely the paraventricular nucleus (PVN) and the lateral hypothalamic area
(LHA), are thought to be especially important (Harrold et al., 2012). The axons
of arcuate NPY/AgRP and POMC/CART neurons project to ‘second-order’
neurons partly located in the PVN, where the anorexigenic neuropeptides
thyrotropin-releasing hormone (TRH), CRH and oxytocin (see section 1.3.3)
are secreted. The PVN represents a major integratory region in the brain
with recognized neuroendocrine, autonomic, and behavioral functions. Preau-
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tonomic PVN neurons project to the liver through both sympathetic and
parasympathetic pathways indicating a pivotal role of the PVN in hepatic
glucose production (O’Hare and Zsombok, 2016). Signals from the PVN are
catabolic and enhance the potency of satiety signals in the NTS leading to
reduced food intake and increased energy expenditure (Woods et al., 2004).
Moreover, the PVN modulates the response to stressors by controlling the
activity of the HPA axis (see section 1.2.2). Lesions of the PVN result in
hyperphagia, reduced energy expenditure, as well as obesity (Shor-Posner
et al., 1985) and PVN dysfunction is also associated with conditions such as
hypertension and congestive heart failure (Ferguson et al., 2008).
The LHA, known as the classical ‘feeding center,’ also receives direct
inputs from the ARC and has a contrasting profile from the PVN (Broberger
et al., 1998). Glucose-sensing neurons in the LHA express the orexigenic pep-
tides melanin-concentrating hormone (MCH) and orexins (see section 1.3.2)
in presence of hypoglycemia (Burdakov et al., 2005). Signals from the LHA,
contrary to the PVN, are anabolic, i.e., suppressing the activity of the satiety
signals in the NTS (Woods et al., 2004). The ventromedial nucleus of the
hypothalamus (VMH), on the other, has been identified as a key target of lep-
tin and therefore referred to as ‘satiety center’ acting on the hypothalamus to
inhibit feeding, increase energy expenditure, and cause weight loss (Schwartz
et al., 1996).
To maintain metabolic homeostasis, the central nervous system requires
a continuous supply of glucose supporting energy requirements of the brain.
An extended network of glucose-sensing neurons detects decreases in glucose
levels and serves to mediate counterregulatory responses restoring euglycemia.
Neurons and neuronal circuits that may be directly or indirectly activated or
inhibited by glucose are located at peripheral sites, e.g., pancreatic α- and
β-cells, liver, carotid body, and gastrointestinal tract, as well as several brain
regions such as the hindbrain, ventromedial hypothalamus, lateral hypotha-
lamus, the ARC, and the suprachiasmatic nucleus (SCN). The SCN of the
hypothalamus, known as ‘the biological clock’ controlling circadian rhythms,
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is responsible for the 24-h rhythm in plasma glucose concentrations with
elevated glucose levels toward the end of the light period and just before the
onset of activity (‘dawn phenomenon;’ La Fleur et al., 1999). The majority
of the glucose-excited neurons are distributed in the lateral hypothalamus,
whereas glucose-inhibited neurons are located ventromedially (Verberne et al.,
2014).
Aside from staving off hunger, i.e., refilling energy stores to ensure an
adequate balance, eating also provides feelings of gratification. The consump-
tion of energy-dense palatable food activates brain circuits of reward and
motivation in limbic and paralimbic areas, e.g., nucleus accumbens (NAcc),
ventral tegmental area (VTA), amygdala, hippocampus, cingulate cortex,
insular cortex, and the striatum. Among several neurotransmitters, e.g., endor-
phins involved in the processing of hedonic aspects of food intake (Volkow
et al., 2011), dopamine is a key neurotransmitter modulating reward mainly
through its projections from the VTA into the NAcc (Wise, 2006). Palat-
able foods, which are high in sugar and fat, serve as potent rewards (Lenoir
et al., 2007) that promote food consumption or even overeating, respectively.
This complementary non-homeostatic pathway in the regulation of eating
behavior is considered particularly important in the development of obesity
(Alonso-Alonso and Pascual-Leone, 2007).
However, homeostatic and non-homeostatic pathways are not completely
separated circuits but rather intricately involved with each other (Rutters
et al., 2012). Neuropeptides involved in homeostatic regulation of food
intake are also implicated in reward-driven, hedonic regulation. For instance,
the adiposity feedback signal leptin (serving as a ‘satiety hormone’), which
informs the hypothalamus of the size of fat stores, has been shown to decrease
food intake after injection into the VTA of rodents (Hommel et al., 2006).
Also ghrelin (referred to as ‘hunger hormone’) influences both homeostatic
and hedonic pathways. As an orexigenic factor synthesized both peripherally
in the gastric mucosa and, to a lower amount, centrally in hypothalamic nuclei
(Cowley et al., 2003; Kojima et al., 1999), ghrelin mediates not only sensations
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of hunger during fasting, but also modulates hedonic aspects of eating, as it
directly targets the VTA (Skibicka et al., 2011).
Apart from these homeostatic and reward circuits which tend to favor food
intake (so called reflexive eating mode), brain areas involved in cognition,
especially the right prefrontal cortex (rPFC), tend to decrease food intake
(reflective eating mode; Alonso-Alonso and Pascual-Leone (2007)). The rPFC
is important for decision making according to social conduct and comprehen-
sion of body-state information at a higher level (Tranel et al., 2002). This
non-homeostatic top-down control from reflective areas can suppress reflex-
ive areas (hypothalamus, brainstem, limbic and paralimbic structures) and
overrule metabolic needs and homeostatic regulatory mechanisms (Berthoud,
2004), e.g., avoiding certain food products because of personal convictions
or judging what is appropriate to eat according to long-term effects on health
and body shape (Alonso-Alonso and Pascual-Leone, 2007). This cognitive
dimension of eating is also assumed to play an essential role in obesity. Le-
sions in the right anterior PFC can cause the ‘gourmand syndrome,’ a passion
for eating (Regard and Landis, 1997), whereas hyperactivity of the rPFC, as
found in patients with right prefrontal focal epilepsy, can lead to anorexia-like
symptoms (Uher and Treasure, 2005).
1.2.2 The hypothalamic-pituitary-adrenal (HPA) axis
The HPA axis is a major neuroendocrine system that controls reactions to
physical and emotional stressors and regulates many homeostatic processes,
including digestion, the immune system, mood and emotions, sexuality, as
well as energy storage and expenditure. Activation of the HPA axis causes
hypophysiotropic neurons localized in the medial parvocellular subdivision of
the PVN of the hypothalamus to produce vasopressin and CRH (Rivier and
Vale, 1983). Vasopressin and CRH stimulate corticotropic cells in the ade-
nohypophysis to secrete the POMC derivative adrenocorticotropic hormone
(ACTH) into the systemic regulation. In response to stimulation by ACTH,
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the zona fasciculata of the adrenal cortex within the adrenal gland produce
and secrete cortisol, a glucocorticoid steroid hormone. Elevated peripheral
cortisol concentrations in turn suppress CRH and ACTH production in the
PVN and the pituitary gland, respectively, in a delayed negative feedback
cycle (De Kloet et al., 1998; Keller-Wood and Dallman, 1984).
Stress in general may lead either to under- or overeating (Razzoli and
Bartolomucci, 2016; Torres and Nowson, 2007). Responses to acute stress
result in reduced food intake in the short term due to physiologic changes,
e.g., slowed gastric emptying and shunting of blood from the gastrointestinal
tract to muscles (Torres and Nowson, 2007). However, prolonged exposure
to chronic stress, e.g., social stress (Scott et al., 2012) or sleep deprivation
(Spiegel et al., 1999), elicits a more passive response driven by the HPA axis.
In the ARC, NPY neurons express glucocorticoid receptors (Hisano et al.,
1988) and chronic central infusion of glucocorticoids induced obesity as well
as increased NPY levels (Zakrzewska et al., 1999).
There is large body of evidence that basal HPA axis function and stress
responsiveness increase during aging. This alteration is possibly the result of
a loss of negative feedback to glucocorticoids, primarily through a decline of
glucocorticoid receptors in hippocampal circuits (Sapolsky, 1999; Sapolsky
et al., 2000), that exert a tonic, inhibitory effect on CRH production by the
hypothalamus (Jacobson and Sapolsky, 1991). In humans, aging is associated
with increased cortisol production (Purnell et al., 2004), and increased cortisol
responses to cognitive challenge (Seeman and Robbins, 1994) resulting in
elevated peripheral cortisol levels which is associated with increased cognitive
decline in elderly humans (Li et al., 2006; Lupien et al., 1999). Apart from that,
HPA axis hyperactivity is also linked to several other medical conditions, such
as major depressive disorder (Keller et al., 2016; McEwen, 2000; Vreeburg
et al., 2009), insomnia (Roth et al., 2007), or pain chronification (Li and Hu,
2016; Sarzi-Puttini et al., 2006). Overall, the data suggest that inappropriate
control of HPA axis function predisposes to metabolic and cognitive disorders.
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1.3 Insulin, orexin A, and oxytocin in the control
of metabolic function
The peptidergic systems that regulate body weight and energy expenditure de-
scribed in section 1.2.1 and 1.2.2 are of great interest as targets for anti-obesity
agents. A staggering number of neuropeptides has been postulated as playing
a role in the orchestration of metabolic processes within the hypothalamus
(Coll and Yeo, 2013), and have been investigated as potential treatments for
obesity (Boughton and Murphy, 2013; Paz-Filho et al., 2015; Sato et al., 2009).
While insulin given by injection is the most common type of medication used
in diabetes treatment, orexin A and oxytocin appear as relatively new targets
in the context of clinical interventions in patients with metabolic disorders
and obesity, respectively. Details about site of synthesis and action, as well
as physiological effects covering their involvement in food intake, insulin
sensitiviy, and HPA axis activity in particular, are provided below.
a b c
Figure 1.2 Peptide crystal structures. Representations of insulin (a), orexin A
(b), and oxytocin (c) showing main chains (ribbons), side chains (sticks), and
solvent-accessible surface areas (transparent).
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1.3.1 Insulin
Insulin (from Latin insula meaning ‘island’) is a peptide hormone (see Fig-
ure 1.2a and Table 1.2) secreted by β-cells of the pancreatic islets in response
to nutritional stimuli and its antidiabetic properties were firstly described by
Paulesco (1921) under the designation ‘pancrein.’ Peripherally, the hormone
promotes the absorption of glucose from the blood into skeletal muscle, white
adipose tissue, and liver while reducing hepatic gluconeogenesis and triglyc-
eride secretion. Insulin triggers lipogenesis in white adipose tissue and liver,
thereby boosting fat storage. Thus, systemic insulin has anabolic properties
by promoting the growth of skeletal muscle and fat mass, but once it has been
transported into the brain compartment, leads to converse catabolic effects by
reducing food intake and adipose mass (Air et al., 2002; Woods et al., 1979).
Insulin enters the brain via saturable transport proportionate to respective
peripheral concentrations (Baura et al., 1993). Insulin receptors (IR) are
expressed in several brain regions, mainly the olfactory bulb, hippocampus,
cerebral cortex, as well as hypothalamic nuclei, e.g., ARC and PVN (Devaskar
et al., 1994; Marks et al., 1990). In the insulin synthesis pathway, proteases
split the precursor proinsulin into equal amounts of insulin and C-peptide.
Thus, C-peptide serves as a measure of endogenous insulin secretion (Jones
and Hattersley, 2013). The insulin monomer consists of two chains, a 21
amino acid residue A-chain and 30 amino acid residue B-chain, linked by
disulfide bonds.
Central insulin administration during food deprivation inhibits the fasting-
induced increase of NPY levels in paraventricular and preproNPY mRNA in
arcuate regions of the hypothalamus (Schwartz et al., 1992). Accordingly,
the catabolic effect of centrally administered insulin is prevented by a POMC
antagonist suggesting that the hypothalamic melanocortin system mediates
the anorexigenic effects of central insulin (Benoit et al., 2002). Neuron-
specific disruption of the IR gene in mice results in diet-sensitive obesity
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with increases in body fat, elevated plasma and leptin levels, and mild insulin
resistance (Brüning et al., 2000).
Beside its involvement in body weight regulation, insulin also has stress-
regulating properties when acting centrally. HPA axis activity strongly de-
pends on the availability of food and energy stores. Basal activity is lowest in
the absence of hunger, whereas fasting is accompanied by elevated basal levels
of the stress hormone corticosterone (Dallman et al., 1995). Insulin is recip-
rocally regulated with corticosterone during stress, suggesting that insulin
provides inhibitory tone to HPA axis activity (Dallman et al., 1995). However,
peripheral insulin administration, e.g., during an euglycemic hyperinsulinemic
clamp, has been repeatedly shown to stimulate HPA axis activity (Chan et al.,
2005; Fruehwald-Schultes et al., 1999, 2001). Intranasal administered insulin,
in contrast, dampened HPA axis secretion (Benedict et al., 2004; Böhringer
et al., 2008; Hallschmid et al., 2008), which points towards divergent central
and peripheral impacts of insulin on HPA axis regulation. HPA axis hyperac-
tivity associated with obesity is likely due to alterations in central signaling
pathways, as obese patients exhibit normal pituitary sensitivity to negative
feedback from glucocorticoids (Pasquali et al., 2002).
1.3.2 Orexin A
Orexins (also referred to as hypocretins) were simultaneously discovered
by two independent research groups as hypothalamus-specific peptides with
a weak homology to the gastrointestinal peptide secretin (de Lecea et al.,
1998; Goodrick, 2015; Sakurai et al., 1998). Orexin A (see Figure 1.2b and
Table 1.2) and orexin B are a pair of 33- and 28-amino acid neuropeptides,
respectively, with 46 % sequence identity, produced by proteolytical cleavage
of the common precursor protein prepro-orexin (Taheri and Bloom, 2001).
Orexin-synthesizing neurons are located in the LHA, perifornical area (PFA),
and the posterior hypothalamus and send projections throughout the brain,
e.g., hippocampus, amygdala, thalamus, NTS, and cerebral cortex (Mieda
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et al., 2013; Sakurai et al., 1998) suggesting that orexins are involved in
various metabolic and behavioral processes. Orexins act via two G protein-
coupled receptors, orexin receptor type 1 (OX1R) and orexin receptor type 2
(OX2R). Orexin A is a high-affinity ligand for both OX1R and OX2R, whereas
orexin B specifically binds to OX2R (Sakurai et al., 1998). In rats, both orexin
receptors are widely expressed in the hypothalamus, including ARC, PVN,
the locus coeruleus, and dorsal raphe nucleus (Trivedi et al., 1998). In rats,
food intake is acutely increased by central administration of orexin A and,
to a lesser extent, by orexin B leading to the initial assumption that both
orexins principally control food intake (Haynes et al., 1999; Sakurai et al.,
1998) which eventually inspired their joint name (derived from ancient Greek
ὄρεξις órexis meaning ‘appetite’). Orexin A may stimulate food intake by
directly activating NPY neurons, which express OX1R (Suzuki et al., 2002),
and suppressing POMC-containing neurons in the ARC (Muroya et al., 2004).
Moreover, the orexin system is strongly implicated in the maintenance
of alertness and wakefulness as well as in the regulation of the autonomic
nervous system, reward system, and glucose/energy homeostasis (Sakurai,
2014b; Saper et al., 2005; Tsuneki et al., 2012). Orexin neurons are most
active during wakefulness and relatively inactive during sleep (Estabrooke
et al., 2001) and a deficiency in the orexin system is supposed to be the cause
for narcolepsy, a chronic neurodegenerative disease chracterized by excessive
daytime sleepiness, periods of rapidly falling asleep, and cataplexies (De
la Herrán-Arita et al., 2011). Narcolepsy in dogs is caused by a mutation
of the OX2R gene (Lin et al., 1999) and genetic ablation of orexin neurons
in mice leads to narcolepsy but also late-onset obesity, despite the presence
of hypophagia (Hara et al., 2001). Accordingly, cerebrospinal fluid (CSF)
orexin A levels are undetectably low in patients with narcolepsy compared to
healthy controls (Ripley et al., 2001).
Orexin mRNA expression correlates negatively with changes in blood
glucose, food intake, and the adipocyte-derived hormone leptin, that provides
the brain with negative feedback on body fat stores (Yamanaka et al., 2003).
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Orexin neurons are inhibited by high extracellular glucose levels which induce
hyperpolarization and decrease membrane resistance (Burdakov et al., 2005).
Food deprivation up-regulates both OX1R and OX2R receptor expression in
the rat hypothalamus (Karteris et al., 2005), whereas genetically obese mice
with elevated basal glucose concentrations show decreased prepro-orexin
gene expression in the LHA compared to controls (Yamamoto et al., 1999).
Accordingly, there is a strong negative correlation between plasma orexin A
and BMI (Adam et al., 2002).
Both orexins stimulate insulin release from pancreatic cells in vitro and in
vivo (Nowak et al., 2000, 2005) and orexin A accordingly inhibits secretion
of glucagon in perfused rat pancreas in situ and isolated pancreatic islets
in vitro (Göncz et al., 2008). Glucagon is synthesized by pancreatic α-
cells in response to hypoglycemia and stimulates hepatic gluconeogenesis to
keep blood glucose levels stable by insulin-antagonistic effects. Moreover,
orexin A stimulates feeding-associated glucose utilization in skeletal muscle
via the sympathetic nervous system (Shiuchi et al., 2009). Thus, orexin A
appears to be simultaneously involved in systemic insulin sensitivity and
hepatic glucose production (Karnani and Burdakov, 2011; Yi et al., 2009)
which seems plausible from an evolutionary point of view; during periods of
starvation, which are accompanied by low energy levels, hypothalamic orexin
neurons stimulate glucose production in the liver to provide energy for the
search for food (Tsuneki et al., 2012; Yi et al., 2009). Furthermore, orexin A
bidirectionally regulates hepatic gluconeogenesis via control of autonomic
balance, contributing to the SCN-controlled daily blood glucose oscillation
(Foppen et al., 2016; Tsuneki et al., 2015; Yamamoto et al., 1984). Orexin A
appears to regulate insulin sensitivity, because orexin knockout mice fed with
normal chow diet show an age-related systemic insulin resistance without
changes in body weight (Tsuneki et al., 2008). Accordingly, patients with
narcolepsy with cataplexy develop metabolic alterations including insulin
resistance, independent of body weight and BMI, respectively (Poli et al.,
2009). Nevertheless, the role of orexin A in glucose homeostasis appears
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contradictory since orexin A is both exerting blood glucose-lowering as well
as -elevating effects seemingly depending on different experimental conditions
(Shiuchi et al., 2009; Tsuneki et al., 2012; Yi et al., 2009).
1.3.3 Oxytocin
The nonapeptide oxytocin (see Figure 1.2c and Table 1.2) is synthesized in
magnocellular neurosecretory cells of the PVN and, to a lesser extent, supraop-
tic nuclei (SON) of the hypothalamus. Stored in large dense-core vesicles
in the neurohypophysis (posterior pituitary gland), oxytocin is released both
into the periphery and to different brain areas by axonal projections and,
more locally, dendritic release and diffusion (Landgraf and Neumann, 2004;
Ludwig and Leng, 2006), thereby acting both as a neuromodulator and a
hormone. Oxytocin neurons are also found in the parvocellular neurons of the
PVN and SCN, in the bed nucleus of the stria terminalis (BST), the medial
amygdala, the dorsomedial hypothalamus, and the locus coeruleus (Stoop,
2012). Oxytocin is a highly conserved neuropeptide in mammals and closely
related to vasopressin which controls water balance and blood pressure, and
only differs by two substitutions in the amino acid sequence at the 3rd and
8th position. Initially, oxytocin has been known for its contribution to labor
induction and lactation. Its cyclic structure and amino acid sequence was
first described by du Vigneaud et al. (1953). The name (derived from ancient
Greek ὠκύς o¯kús and τόκος tókos meaning ‘quick birth’) is based on its
uterine-contracting properties (Dale, 1906). Oxytocin has been identified
as an important regulator of psychosocial function in humans modulating
trust, attachment, emotion recognition, and sexual behavior (Behnia et al.,
2014; Kosfeld et al., 2005; Meyer-Lindenberg et al., 2011; Scheele et al.,
2012; Shahrestani et al., 2013; Thienel et al., 2014) which earned it the label
‘trust, love, or cuddle hormone.’ However, oxytocin also stimulates defen-
sive aggression toward group-outsiders (De Dreu et al., 2010) and promotes
group-serving dishonesty (Shalvi and De Dreu, 2014) suggesting that oxy-
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tocin as well exerts opposing influences on human behavior in different social
contexts.
While research in humans in particular brought the social role of oxytocin
into prominence, animal experiments moreover revealed a contribution of the
hormone to ingestive behavior and metabolism (Arletti et al., 1989; Morton
et al., 2012; Olson et al., 1991; Wu et al., 2012). Thus, studies in rodents
have shown that oxytocin strongly inhibits food intake and is involved in
energy expenditure and glucose homeostasis (Morton et al., 2012). Oxytocin
stimulates insulin secretion (Altszuler and Hampshire, 1981; Björkstrand et al.,
1996) and is assumed to mediate the food intake–limiting effect of leptin in
the PVN (Blevins et al., 2004) and oxytocin mRNA levels were reduced
by fasting and restored by leptin (Tung et al., 2008). Moreover, oxytocin
neurons in the PVN are a major target of the anorexigenic peptides nesfatin-1
(Maejima et al., 2009) and α-MSH (Sabatier et al., 2003). Central injection
of nesfatin-1 and α-MSH stimulated oxytocin release from the dendrites of
hypothalamic neurons while the firing rate of oxytocin neurons was inhibited
and thus reduced secretion from the neurohypophysis suggesting that oxytocin
signaling is mediated by nesfatin-1 through a leptin-independent melanocortin
pathway (Maejima et al., 2009; Sabatier et al., 2003).
Oxytocinergic neurons also project to mesolimbic reward-processing cen-
ters, such as the caudal part of the VTA, NAcc, and ventral striatum (Stoop,
2012; Succu et al., 2008). Sugar intake, which is partly driven by its hedonic
qualities, in parallel increases dopamine levels in the NAcc (Hajnal et al.,
2004) and enhances oxytocinergic gene expression in the PVN (Olszewski
et al., 2009) and additionally the oxytocin system is activated more strongly by
intake of sucrose compared to bland chow (Mitra et al., 2010). Accordingly,
exogenously administered oxytocin reduces dopamine turnover in NAcc and
striatum (Qi et al., 2008), indicating that oxytocin might control especially
the reward-related intake of highly palatable food (Klockars et al., 2015).
Oxytocin as well modulates HPA axis activity both at basal and stress-
ful conditions. In the PVN, oxytocin inhibits the release of CRH which
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subsequently reduces downstream ACTH and glucocorticoid release result-
ing in an overall dampening of HPA axis activity (Engelmann et al., 2004).
Suckling-induced increases in plasma oxytocin levels are associated with
attenuated baseline levels of plasma ACTH and cortisol postpartum lactating
women (Amico et al., 1994; Chiodera et al., 1991). Furthermore, infusion
of exogenous oxytocin in men decreased plasma ACTH and cortisol levels
in a dose-dependent manner (Legros et al., 1984) suggesting that peripheral
oxytocin regulates HPA axis activity at the pituitary or adrenal gland level.
Intranasal administration of oxytocin likewise reduces cortisol levels during
couple conflict (Ditzen et al., 2009), physical stress (Cardoso et al., 2013), and
the Trier Social Stress Test in the presence of social support (Heinrichs et al.,
2003). The mechanism underlying the attenuating effect of intranasally ad-
ministered oxytocin on HPA axis activity seems less clear, possibly involving
both central and peripheral domains.
1.4 Intranasal delivery of substances to the cen-
tral nervous system
The methodological question arises how neuropeptides can be applied to
reach the central nervous system in the most effective and least harmful way
possible. Animal research allows neuropeptides to be administered directly
to the central nervous system (CNS) via stereotactic, e.g., intracerebroven-
tricular (ICV) infusion (Blevins et al., 2016; Haynes et al., 1999; Woods
et al., 1979). Since this invasive technique is associated with significant health
risk, this route of delivery cannot be routinely employed in a human study
context (Cook et al., 2009). So far, the conventional way of increasing central
nervous neuropeptidergic concentrations to investigate central effects in the
human brain relies on intravenous (IV) infusion. But the experimental and
therapeutical use of neuropeptides underlies several limitations when admin-
istered systemically. These compounds do not readily pass the blood-brain
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barrier (BBB), and evoke potent hormone-like, peripheral side effects when
circulating in the blood (Illum, 2003). For instance, systemic insulin infusion
results in a drop of glucose levels, i.e., hypoglycemia, triggering the graded
activation of endocrine stress axes that can affect brain function (Tesfaye and
Seaquist, 2010) and IV administration of oxytocin induces (painful) uterine
contractions together with antidiuretic and vascular effects when used in large
doses (Shyken and Petrie, 1995).
A solution for bypassing the methodological restrictions of IV admin-
istration is provided by the use of intranasal (IN) administration which has
been described in several animal paradigms (Dhuria et al., 2009; Parker et al.,
2005; Thorne et al., 2004). In humans, neuropeptides have been shown to
achieve access to the central nervous system (CNS) within one hour after
IN administration (Born et al., 2002). It is assumed that intranasally admin-
istered neuropeptides reach the CNS primarily via extracellular transport
mechanisms along olfactory sensory neurons (see Figure 1.3). Administered
molecules diffuse into the subarachnoid space across the olfactory epithelium
and travel alongside intercellular clefts between sustentacular (supporting)
cells and olfactory neurons thus crossing the olfactory epithelium (Dhuria
et al., 2010). The extracellular pathway is considered as the most important
one for the effects of IN administered neuropeptides on brain function (Spetter
and Hallschmid, 2015). Small, lipophilic molecules or molecules that are
recognized by the membrane, e.g., insulin (Lacroix et al., 2008), may also
cross the olfactory epithelium transcellularly via intracellular transport mech-
anisms involving the uptake into olfactory neurons by passive diffusion or
receptor-mediated transcytosis followed by axonal transport to the olfactory
bulb. However, this intraneuronal pathway takes several hours to days for IN
administered peptides to reach the brain via the olfactory bulb (Baker and
Spencer, 1986; Dhuria et al., 2010).
Besides physicochemical properties (lipophilicity, hydrophilicity, etc.), the
molecular mass of intranasally administered substances is the most important
factor affecting the absorption through the nasal mucosa and their bioavail-
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Figure 1.3 (Previous page.) Peptide molecules (light blue circles) reach the
mucus of the nasal cavity, which is innervated by both olfactory neurons and
sensory branches of the trigeminal nerve (maxillary nerve). The olfactory
epithelium consists of olfactory sensory neurons, sustentacular cells (sup-
porting cells), and basal cells. Peptides can be transported through the nasal
mucous membrane and the olfactory bulb to the central nervous system (CNS)
intra- and extracellularly by traveling along olfactory neurons and trigeminal
nerves as well as by entering perivascular (surrounding) channels of brain’s
blood vessels in the lamina propria. Due to the nasal mucosa’s high degree
of vascularisation, intranasally administerd peptides can be absorbed into the
network of blood vessels located underneath the basement membrane and into
the systemic circulation. Mucociliary clearance mechanisms transport peptide
molecules with the mucus towards the nasopharynx for elimination (figure is
based on Guastella et al., 2013). Abbreviations: CNS, central nervous system.
ability (Arora et al., 2002). Thus, the intranasal delivery of insulin, orexin A,
and oxytocin, which have molecular weights of 5.8 kDa, 3.6 kDa, and 1 kDa,
respectively, can be expected to differ due to their specific physicochemical
properties (see Table 1.2). Passage of IN administered peptides to the CNS
can also be established along the trigeminal nerve (Liu et al., 2012; Thorne
et al., 2004), which also innervates the nasal cavity via parasympathetic fi-
bres. Due to the nasal mucosa’s high degree of vascularisation, intranasally
administered substances can also be delivered to systemic circulation via
absorption into the network of capillary blood vessels located underneath
the basement membrane, resulting in problems related to drug elimination
via hepatic and renal mechanisms, plasma protein binding, proteolysis, and
potential peripheral side effects. A subsequent delivery across the BBB to
the CNS is possible rather for small, lipophilic compounds than for large,
hydrophilic molecules such as peptides and proteins (Dhuria et al., 2010).
However, intranasally administered peptides can also reach the brain by en-
tering perivascular compartments surrounding cerebral blood vessels in the
nasal cavity and are rapidly distributed throughout the CNS via bulk flow
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mechanisms (Lochhead et al., 2015). Finally, mucociliary clearance mecha-
nisms transport a small amount of nasally administered neuropeptides with
the mucus to the nasopharynx, where they are swallowed and transported to
the lungs and the stomach via the trachea and the esophagus, respectively
(Guastella et al., 2013).
1.5 Aims and hypotheses
Insulin sensitivity, body weight, and HPA axis activity are considered signifi-
cant determinants of metabolic diseases associated with increased mortality
and chronic morbidity (Kaur, 2014). As stated above, animal models have
shown that insulin, orexin A, and oxytocin directly administered to the brain,
play significant roles in the regulation of food intake, glucose metabolism, and
HPA axis regulation. In humans, the nasal delivery seems to be a favorable
way for direct drug delivery to the central nervous system (Born et al., 2002;
Dhuria et al., 2010). While intranasally administered insulin and oxytocin
may be considered as the most thoroughly investigated peptides regarding
their potential for the enhancement of brain functioning in humans (Chapman
et al., 2013; Spetter and Hallschmid, 2015), the current scientific output for
IN administration of orexin A in the human setting as yet is relatively sparse.
The aim of the present thesis was to evaluate the effects on metabolic con-
trol of intranasally administered insulin, orexin A, and oxytocin in healthy
normal-weight, young men. Moreover, effects in obese men as well as elderly
individuals were obtained to further explore possible therapeutic fields of
application. Three studies were performed for this purpose (see Figure 1.4).
Study I aimed at the contribution of central nervous oxytocin administra-
tion to the control of food intake in obese individuals. Animal studies (Blevins
et al., 2015; Morton et al., 2012) and pilot experiments in humans (Lawson
et al., 2015; Ott et al., 2013) indicate that the hypothalamic neuropeptide
oxytocin limits food intake. Notably, Ho and Blevins (2013) suggest that the
metabolic effects of oxytocin may be even enhanced in diet-induced obese
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compared to control animals. These findings raise the question of oxytocin’s
potential to improve metabolic control in obesity. We therefore investigated
the impact of oxytocin via the intranasal route (24 IU) on eating behavior and
metabolic function in obese men and compared the results with the effects in
normal-weight men obtained in a former study by our group (Ott et al., 2013),
where oxytocin exerted an acutely inhibitory impact on palatable snack intake.
We applied a validated paradigm including the measurement of ad libitum
food intake from a breakfast buffet 45 min after oxytocin administration, fol-
lowed by the assessment of postprandial, reward-driven snack intake. In this
study we formulated the following hypothesis: In men with obesity, intranasal
oxytocin administered in the fasted state reduces overall ingestive behavior
and this inhibitory effect is even more salient in comparison to normal-weight
subjects.
Study II focused on the effect of central insulin on HPA axis activity.
Intranasal administration of insulin is known to curb stress axis activity in
young (obese) subjects (Böhringer et al., 2008; Hallschmid et al., 2008). Apart
from obesity, maladaptive increases in HPA axis activity that predispose to
metabolic and cognitive disorders are also strongly associated with aging
(Lupien et al., 1999; McEwen, 2000; Seeman and Robbins, 1994). Changes
in sleep-associated neuroendocrine secretion patterns that emerge in older
age are assumed to be pathophysiological factors in metabolic and cognitive
impairments. In this regard, increased activity of the HPA stress axis, which
follows a circadian pattern with nadir values during early sleep, may be
particularly detrimental. Study II aimed to investigate the effect of intranasal
insulin on HPA axis activity of elderly and young subjects in the first night-
half, when nadir concentrations of ACTH and cortisol reflect basal HPA axis
secretion. Intranasal insulin (160 IU) was administered to elderly (mean age
70.0 years) and young (23.6 years) healthy subjects at 2230 h, 30 min before
bedtime. Considering the association between increased age and nocturnal
HPA axis hyperactivity (Van Cauter et al., 2000) as well as impaired central
nervous insulin signaling (Biessels and Reagan, 2015), it was hypothesized
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that intranasal insulin administered before sleep onset has an inhibitory effect
on ACTH and cortisol secretion during early sleep particularly in elderly
subjects.
The purpose of Study III was to elucidate the influence of orexin A on
glucose homeostasis in humans. Orexin A is crucially involved in the control
of sleep/wake regulation, feeding behavior, reward processing and energy
homeostasis (Sakurai, 2014a,b). Its contribution to glucose homeostasis has
not been clarified, although observations in animal studies have led to the
assumption that orexin A may improve glucose tolerance and insulin sensi-
tivity (Ducroc et al., 2007; Tsuneki et al., 2012). Using a standardized 2-h
oral glucose tolerance test (OGTT) in Study III, we investigated the acute glu-
coregulatory effect of intranasal administered orexin A (500 nmol) in healthy
young subjects with normal glucose tolerance (NGT). It was hypothesized
that orexin A has an inhibitory effect on blood glucose excursion and insulin
levels in response to glucose challenge.
Hypotheses
1. IN oxytocin reduces homeostatic- and reward-driven food intake in
obese men.
2. IN insulin attenuates basal HPA axis activity during early sleep in young
and elderly individuals.
3. IN orexin A improves glucose tolerance during an OGTT in healthy
young men.
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Figure 1.4 Intranasal administration of neuropeptides to assess their contribu-
tion to metabolic control. In the present thesis, the effects of the hypothalamic
neuropeptides oxytocin and orexin A as well as of the pancreatic peptide
insulin, when administered intranasally, on metabolic function were inves-
tigated, i.e., on food intake, HPA axis activity, and insulin sensitivity. The
intranasal administration route bypass the blood-brain barrier and represents a
feasible, non-invasive approach of directly targeting the CNS while systemic
side effects are (largely) avoided (figure adapted and modified from Spetter
and Hallschmid, 2015).
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2.1 Introduction
Oxytocin, a hypothalamic nonapeptide which is released into the circulation
through the posterior pituitary and also directly acts on central nervous re-
ceptors, regulates reproductive functions like mother-infant interaction and
lactation and is a potent modulator of social behaviors including attachment
and sexual behavior (Meyer-Lindenberg et al., 2011). Studies in animals and
pilot experiments in humans have indicated that oxytocin moreover might
play a role in the regulation of eating behavior and metabolism. In rodents
(Morton et al., 2012) and rhesus monkeys (Blevins et al., 2015) with normal
weight, but also with diet-induced obesity, subcutaneous oxytocin administra-
tion inhibits food intake, increases energy expenditure and reduces glucose
levels. Interestingly, experiments in rodents suggest that the metabolic effects
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of oxytocin may be even enhanced in diet-induced obese in comparison to
control animals (Ho and Blevins, 2013). In studies in humans, intranasal
oxytocin attenuated reward-driven snack intake and decreased postprandial
glucose concentrations in normal-weight men (Ott et al., 2013). Against
this background, and considering that available weight loss treatments are of
modest or temporary efficacy (Halpern and Halpern, 2015; Miras and le Roux,
2014), the intranasal administration of oxytocin to the human brain, which in
a broad range of studies has been demonstrated to be associated with absent
or minimal side effects (MacDonald et al., 2011), might be a promising phar-
macological intervention in obesity (Blevins and Baskin, 2015; Lawson et al.,
2015; Zhang et al., 2013).
In the present study, we investigated the impact of oxytocin on eating
behavior in obese men and compared the results to the effects obtained in
normal-weight men (Ott et al., 2013). Since ingestive behavior is homeostat-
ically regulated in response to energy depletion as well as by brain circuits
processing the reward-related, ‘hedonic’ qualities of food intake (Berthoud
et al., 2011; Morton et al., 2014), we applied a validated paradigm that in-
cludes a breakfast buffet presented to fasted participants (Hallschmid et al.,
2010; Schultes et al., 2005), as well as the delayed assessment of food intake
from snacks (Hallschmid et al., 2012; Higgs et al., 2008). In addition, en-
ergy expenditure, glucose homeostasis and HPA axis secretory activity were
measured before and after oxytocin administration as well as after breakfast
intake.
2.2 Methods
Subjects
Eighteen healthy obese men were recruited and their results compared to the
findings in 20 normal-weight men, which were obtained with an identical ex-
perimental set-up and are described in detail in Ott et al. (2013). Subjects were
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recruited via mailing lists and advertisements in local newspapers. Relevant
illness was excluded by medical history and clinical examination. Habitual
eating behavior of obese subjects was assessed via a lifestyle questionnaire on
dietary restraint and tendency toward disinhibition. Dietary restraint, i.e., the
conscious effort to restrict calorie intake to control body weight, was assessed
using the restraint scale of the Dutch Eating Behavior Questionnaire (DEBQ-
R; van Strien et al., 1986). Tendency toward disinhibition was assessed
with the disinhibition scale of the Three Factor Eating Questionnaire (TFEQ;
Stunkard and Messick, 1985). On average, participants achieved a DEBQ-R
score (mean±SEM) of 2.55± 0.13 and a TFEQ score of 6.53± 0.80. The
propensity to consume palatable foods was measured at three levels of food
proximity (food available, food present, and food tasted) with the Power of
Food Scale (PFS; Lowe et al., 2009) at each session (see Table 2.1 for subject
characteristics). Subjects were kept unaware of hypothesized treatment effects
on food intake and were informed that the experiments concerned the effect
of oxytocin on mood, taste preferences and energy expenditure. Participants
gave written informed consent to the study that conformed to the Declaration
of Helsinki and was approved by the local ethics committee.
Experimental procedure
Experiments were carried out in a balanced, double-blind, cross-over, within-
subject comparison. Each subject participated in two experimental sessions
(oxytocin and placebo) spaced at least 10 days apart. Participants were in-
structed to abstain from the intake of food and caffeinated and alcoholic
beverages after 2000 h on the day preceding each session.
After the subject’s arrival at the laboratory at ∼0800 h, a venous cannula
was inserted into the subject’s non-dominant arm to enable drawing of ve-
nous blood (see reffig:inoxy1 for the experimental procedure). Thereafter,
blood was sampled for baseline assessments of hormonal parameters. At
0942 h each subject was intranasally administered 24 IU oxytocin (0.6 ml
Syntocinon®; Defiante Farmacêutica, Funchal/Madeira, Portugal) or placebo
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(0.6 ml vehicle containing all Syntocinon ingredients except for the peptide)
at 6 individual 0.1 ml-puffs (3 per alternating nostril) with 30-s intervals in-
between. Forty-five minutes after administration, subjects were presented
with a free-choice ad libitum breakfast buffet from 1030–1100 h. Casual
snack intake was assessed 95 min later under the pretext of a snack taste test.
Olfactory function was tested at 1200 h. Feelings of hunger, mood, subjective
well-being and the perceived experimenter’s trustworthiness were repeatedly
rated on visual analogue scales (0–100) and energy expenditure was assessed
by indirect calorimetry before and after substance administration and after the
test breakfast. Heart rate and blood pressure were monitored. At the end of
the experiments, subjects were asked to indicate their account of the study
purpose and if they thought to have received oxytocin or placebo.
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Figure 2.1 Experimental procedure. After baseline assessments of blood pa-
rameters, psychological variables, vigilance, and energy expenditure, subjects
were intranasally administered oxytocin (24 IU) and placebo, respectively, at
0942 h (nose symbol). At 1030 h, 45 min after substance administration, sub-
jects were allowed to eat ad libitum from a free-choice test buffet for 30 min.
About 60 min after termination of the buffet, at 1200 h, olfactory function was
assessed, and at 1235 h, 95 min after the end of the buffet, snack intake was
measured under the pretext of a taste-rating task. Throughout the sessions,
mood, hunger, thirst, and vigilance were assessed, and blood samples were
taken (syringe symbols).
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Assessments of food intake
The breakfast buffet comprised a collection of bread and rolls, spreads (e.g.,
jam, honey), sausages, cheese, fruits, puddings, fruits, milk and juice, which
totaled 4562 kcal (see Table 2.2 for details). Subjects were left undisturbed
during breakfast and were not aware that their food intake was measured by
weighing buffet components before and after. This procedure enables the
precise assessment of primarily hunger-driven food intake in the fasted state
(Hallschmid et al., 2010; Ott et al., 2013; Schultes et al., 2005). Reward-
related eating in the relative absence of hunger was assessed under the pretext
of a taste test (Hallschmid et al., 2012; Higgs et al., 2008; Ott et al., 2013) that
included snacks of three different types but comparable calorie content and
macronutrient composition, i.e., ‘TUC Cracker Classic’ (salty taste; Griesson-
de Beukelaer, Polch, Germany; 486 kcal per 100 g; 63 g carbohydrates per
100 g), ‘Rice Waffles’ (bland taste; Continental Bakeries B.V., Dordrecht, The
Netherlands; 390 kcal per 100 g; 63 g carbohydrates per 100 g), and ‘Double
Chocolate Cookies’ (sweet taste; EDEKA, Hamburg, Germany; 500 kcal per
100 g; 57.2 g carbohydrates per 100 g). For each variety, 15 snacks broken
into bite size pieces were provided on a separate plate, and labeled snack
A, B, and C, respectively, allowing for a considerable amount to be eaten
without the plates appearing empty, to ensure that participants would not
restrict snack intake based on whether the experimenter could see how much
had been consumed. The participant was instructed to taste and rate each
snack type on a visual analog scale (VAS) anchored by 0 (not at all) and
100 mm (very palatable/sweet/salty). Subjects were informed that during and
after completion of the rating they could eat as many snacks as they liked
because remaining food would be discarded, and were left alone for 10 min.
Intake was covertly measured by weighing the snacks before and after the
test.
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Measurement of hunger, thirst, mood, vigilance, and olfactory function
Hunger, thirst, and the perceived trustworthiness of the experimenter were
rated on VAS (0–100 mm). Self-reported mood was assessed on 5-point
scales covering the categories good/bad mood, alertness/sleepiness and calm-
ness/agitation (MDBF; Steyer et al., 1997). In the 5-min PC-based vigilance
task (Diekelmann et al., 2011), a red dot appears at random intervals either on
the left or the right side of the screen, and subjects are required to press the
respective key as fast as possible, receiving immediate feedback in the form
of the reaction time for correct responses or an error message. Mean reaction
time was registered and adjusted for mistakes by adding the square root of the
product of the mean reaction time and the number of mistakes. Olfactory func-
tion was tested 60 min after the test buffet with the validated Sniffin’ Sticks
commercial test kit (Burghart Elektro- und Feinmechanik GmbH, Wedel, Ger-
many) that covers the three dimensions of olfactory threshold, discrimination,
and identification (Hummel et al., 2007).
Measurement of energy expenditure, plasma glucose and hormonal pa-
rameters
Resting energy expenditure (expressed as kcal per day) and the respira-
tory quotient were measured via indirect calorimetry using a DeltaTrac II
ventilated-hood system (SensorMedics Vmax 29n; VIASYS® Healthcare,
Yorba Linda, CA, USA). Before each use, the device was calibrated with
calibration gas to 5 % CO2 and 95 % O2. Calorimetric measurements (30 min
each) took place at 0910 h (baseline), immediately after intranasal substance
administration at 0945 h to assess effects of intranasal oxytocin alone, and
again at 1110 h (that is, after the ad-libitum test buffet) to register postpran-
dial energy expenditure. Substrate utilization in the obese participants was
calculated based on the following stoichiometric equations: carbohydrate
oxidation (g/min) = 4.21×VCO2− 2.962×VO2− 0.4× n; fat oxidation
(g/min) = 1.695×VO2− 1.701×VCO2− 1.77× n where n represents ni-
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trogen excretion from protein oxidation (estimated at 135µg×kg×min−1;
Jeukendrup and Wallis, 2005).
Blood samples obtained in the obese participants to assess serum insulin,
C-peptide, cortisol and growth hormone, as well as plasma glucose, lactate,
ACTH and non-esterified fatty acids (NEFA) were centrifuged, and sam-
ples were stored at −80 ◦C. Concentrations of glucose and lactate in fluoride
plasma were determined with the ADVIA® Chemistry XPT clinical chemistry
analyzer according to the hexokinase and colorimetric lactatoxidase method,
respectively. Serum insulin, C-peptide and cortisol concentrations were mea-
sured with the ADVIA® Centaur XPT immunology analyzer and concentra-
tions of growth hormone and ACTH were measured using the Immulite® 2000
XPi Immunoassay-System. Plasma NEFA were determined according to the
ACS-ACOD method (NEFA-HR(2), Wako Chemicals GmbH, Neuss, Ger-
many) with the ADVIA® Chemistry XPT clinical chemistry analyzer (all
instruments from Siemens Healthcare Diagnostics, Eschborn, Germany).
Statistical analysis
Analyses were generally based on analyses of variance (ANOVA) with the
between-subject factor ‘group’ (obese/normal weight) and the within-subject
factors ‘treatment’ (oxytocin/ placebo), ‘time,’ ‘nutrient’ (carbohydrates/pro-
tein/fat), ‘food type’ (savory/sweet/neutral), ‘snack type’ (salty/sweet/bland)
and ‘taste’ (salty/sweet) as appropriate. Note that comparisons between groups
focused on the main parameters of energy intake and expenditure; for detailed
results of normal-weight subjects see Ott et al. (2013). Degrees of freedom
were corrected using the Greenhouse-Geisser procedure. Areas under the
curve (AUC) were calculated according to the trapezoidal rule. Significant
ANOVA and AUC effects were specified by pairwise two-sided t-tests. For
blood parameters, baseline adjustment was achieved by subtracting individual
baseline values from individual post-intervention measurements. All data are
presented as means±SEM. A P value < 0.05 was considered significant.
2.3 Results 39
2.3 Results
Oxytocin reduces food intake to a greater extent in obese than normal-
weight men
In the obese subjects, oxytocin in comparison to placebo reduced overall food
consumption from the breakfast buffet by ∼10 % (F(1,17) = 5.26, P < 0.04
for treatment; Table 2.3 and Figure 2.2a and b). In contrast, the normal-
weight subjects did not alter their breakfast intake after oxytocin administra-
tion (P > 0.6 for all comparisons including treatment×macronutrients and
treatment× food types; F(1,36) = 3.48, P = 0.07 for group× treatment). The
difference between obese and normal-weight men in the hypophagic effect
of oxytocin especially concerned the intake of carbohydrates (F(1,36) = 4.44,
P = 0.042 for group× treatment). In the obese subjects alone, oxytocin did
not exert differential effects on the intake of macronutrients or food types
(all P > 0.3). In general, obese ate more than normal-weight participants
in the respective placebo conditions (F(1,36) = 4.27, P < 0.05 for group), in
particular more carbohydrates and proteins (F(2,72) = 9.25, P < 0.001 for
group×macronutrient). In both groups, hunger ratings were comparable at
baseline (P > 0.2) and generally unaltered by oxytocin (P > 0.9), falling to
comparably low values of around 12 % of the maximal score after breakfast
(P > 0.2; F(1,36) = 350.54, P < 0.001 for time; P > 0.12 for treatment ef-
fects). Thirst ratings were likewise unaffected by oxytocin (P > 0.4 for all
comparisons).
In the snack test during the postprandial period, oxytocin in comparison to
placebo induced a reduction in total snack intake of 22 % across all subjects
(F(1,36) = 13.37, P < 0.001 for treatment; Table 2.3 and Figures 2.2c and d).
This effect did not differ between the obese and the normal-weight groups
(F(1,36) = 0.01, P > 0.9) although it was of a greater statistical effect size in
the obese (F(1,17) = 9.89, P = 0.006; ω2p = 0.31) compared with the normal-
weight participants (F(1,19) = 5.5, P = 0.03; ω2p = 0.18). In both groups,
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it was especially pronounced for chocolate cookie consumption (F(2,56) =
3.88, P < 0.04 for treatment× snack type; Table 2.3; Figure 2.2d). The
oxytocin-induced reductions in total and chocolate snack intake found in
the obese subjects remained significant when corrected for total calorie and
carbohydrate consumption during the preceding breakfast buffet (both P6
0.003). Although breakfast and snack consumption per se were unrelated
in both conditions (P > 0.4), the oxytocin-induced reduction in breakfast
intake was inversely related to the respective attenuation of snack intake
(r =−0.48, P < 0.05). Intake and rated palatability of chocolate cookies by
far exceeded those of the remaining snacks when analyzed across conditions
in the obese subjects (F(1,17) = 70.52, P < 0.001 for snack type). Sweetness
and saltiness ratings were highest for chocolate cookies and salt crackers,
respectively (F(2,34) = 221.28, P < 0.001 for snack type× taste). Generally
comparable rating patterns were obtained in the normal-weight subjects (P >
0.15 for all group comparisons). Oxytocin did not affect ratings for chocolate
cookies and salt crackers (all P > 0.15) in the obese but increased the rated
palatability (placebo, 2.89±0.50; oxytocin, 3.82±0.47; P < 0.03) and, to
a lesser extent, perceived sweetness of rice waffles (placebo, 1.74± 0.40;
oxytocin, 2.63±0.61; P < 0.06).
Energy expenditure is not acutely affected by oxytocin administration
Oxytocin did not alter resting energy expenditure assessed by indirect calori-
metry during the entire experimental period in the obese (F(1,17) = 0.03, P >
0.87 for treatment× time; F(1,17) = 0.32, P > 0.58 for treatment; Figure 2.2f)
and the normal-weight subjects (all P > 0.12; F(1,36) = 0.47, P > 0.49 for
group× treatment× time). The rise in energy expenditure by ∼22 % found
in the obese subjects between the fasting state (baseline) and the postprandial
state reflects diet-induced thermogenesis (that is, the energy emitted as heat
during metabolizing of food; F(1,17) = 200.91, P < 0.001 for time). In the
postprandial period, oxytocin compared with placebo appeared to decrease
respiratory quotient (placebo, 0.90±0.02; oxytocin, 0.83±0.02) and carbo-
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Figure 2.2 (Previous page.) Upper panels indicate mean±SEM total intake
(kcal) from the test breakfast after placebo (white bars) or oxytocin (black
bars) administration in obese (n = 18) and normal-weight men (n = 20) (a)
and individual total food intake with values of both sessions connected by
lines in obese men (b), as well as total snack intake in obese and normal-
weight men (c). Lower panels depict, in the group of obese men, snack intake
(kcal) according to snack categories (d), individual total snack intake with
individual values of both sessions connected by lines (e), as well as resting
energy expenditure during the baseline (0910–0940 h), post-treatment (0945–
1015 h), and postprandial periods (1110–1140 h) (f). #P < 0.08, ∗P < 0.05,
∗∗P < 0.01 for comparisons between conditions (pairwise two-sided t-tests).
hydrate utilization (placebo, 0.26±0.03g/min; oxytocin, 0.17±0.02g/min;
both P = 0.02) whereas increasing fat utilization (placebo, 0.05±0.01g/min;
oxytocin, 0.10±0.01g/min; P = 0.01) in the obese group. However, these
effects were no longer significant when the analysis of respiratory quotient
was corrected for total breakfast calorie intake and analyses of carbohydrate
oxidation and fat utilization were corrected for carbohydrate and fat intake,
respectively (all P > 0.17).
Oxytocin reduces HPA axis activity and the glucose response to food in-
take in obese and normal-weight subjects
During baseline, none of the blood parameters differed between conditions
(all P > 0.18). Oxytocin exerted a suppressive effect on fasting HPA axis
activity in the obese men, reducing plasma ACTH and serum cortisol con-
centrations between administration and breakfast intake (F(1,17) = 6.20, P =
0.02; F(1,17) = 5.81, P < 0.03, respectively, for treatment effects, and t(17) =
2.65, P < 0.02; t(17) = 2.30, P = 0.03, respectively, for the difference in
AUC0930–1025 h; Figures 2.3a and b), whereas concentrations were comparable
between conditions after breakfast (all P> 0.12 for respective comparisons).
In the normal-weight individuals respective effects extended to the postpran-
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dial period (Ott et al., 2013) but still were largely comparable to the pattern
found in obese subjects (P > 0.14 for respective group× treatment interac-
tions). Supplementary analyses in the group of obese subjects indicated
that the oxytocin-induced decreases in preprandial cortisol concentrations
(AUC0930–1025 h) were not significantly correlated with measures of break-
fast intake (all P > 0.72). Likewise, decreases in postprandial cortisol levels
(AUC1100–1145 h) were not significantly correlated with cookie intake (all
P > 0.12, Pearson’s coefficients).
Circulating concentrations of glucose, lactate, insulin, and C-peptide
showed the expected meal-related increases across conditions in the obese
participants (all P < 0.001 for time; Figures 2.3c–e). Whereas levels of lac-
tate, insulin, and C-peptide were not affected by oxytocin administration (all
P > 0.19), oxytocin exerted a sustained suppressive effect on glucose levels
during the postprandial period (F(3,50) = 3.77, P < 0.02 for treatment× time;
Figure 2.3c). This effect was still evident when adjusted for preceding to-
tal and carbohydrate-specific breakfast intake (both P < 0.05), but statisti-
cally unrelated to the oxytocin-induced decrease in cortisol concentrations
(P > 0.43). An oxytocin-triggered reduction in postprandial glucose levels
was likewise found in normal-weight individuals (F(1,36) = 0.15, P = 0.7
for group× treatment). In the obese subjects, total plasma NEFA concentra-
tions were suppressed after breakfast intake (F(1,19) = 131.42, P < 0.001 for
time) without significant treatment effects (P > 0.67; Figure 2.3f); circulating
concentrations of growth hormone were comparable between conditions (all
P > 0.24).
Olfactory performance, mood, vigilance, perceived trustworthiness, and
treatment awareness
In the olfactory task, no treatment effects on perceptual thresholds, olfactory
discrimination and olfactory identification emerged in the obese participants
(all P > 0.17). Self-rated mood, reaction times in the vigilance task and
the perceived trustworthiness of the experimenter were likewise unaffected
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Figure 2.3 (Previous page.) Mean±SEM concentrations of plasma adreno-
corticotropic hormone (a), serum cortisol (b), plasma glucose (c), serum
insulin (d), serum C-peptide (e) and plasma NEFA (f) assessed before (av-
eraged across the 0915 h and 0930 h baseline values) and after intranasal
administration (vertical dotted line) of oxytocin (24 IU; black circles and
solid lines) and placebo (vehicle; white circles and dotted lines) in obese men
(n = 18). Subjects ate a test breakfast from 1030–1100 h and ingested snacks
under the pretext of a taste test from 1235–1245 h. Mean baseline values of
both conditions are averaged to a common baseline. ∗P < 0.05, tP < 0.1 for
comparisons between conditions (pairwise two-sided t-tests).
(all P > 0.27). Eight of the 18 participants (44 %) correctly guessed their
respective treatment conditions (χ2(3;N=18) = 2.68, P> 0.6), indicating that the
participants overall gained no treatment awareness. All of these results were
well comparable with the findings in the group of normal-weight subjects (Ott
et al., 2013).
2.4 Discussion
We demonstrate that the acute intranasal administration of oxytocin inhibits
reward- but also hunger-driven food intake in obese men and that this effect
is not compensated by changes in energy expenditure. In normal-weight
men, the oxytocin-induced reduction in calorie consumption was restricted to
snacking, indicating that the inhibitory effect of oxytocin on food intake is
generally larger in obese than normal-weight subjects. Oxytocin moreover
attenuated secretory activity of the HPA axis and curbed the postprandial
excursion of glucose levels in obese and normal-weight men, suggesting an
insulin-sensitizing action of the hormone.
Oxytocin has been shown in a number of experiments in rodents to inhibit
feeding after intracerebroventricular injection (Arletti et al., 1989; Olson
et al., 1991) as well as after peripheral administration, which both supposedly
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trigger hypothalamic oxytocin release in a feedforward fashion (Maejima
et al., 2011; Morton et al., 2012). Recently, comparable effects have been
obtained after intranasal administration (Maejima et al., 2015). Oxytocin’s
restraining effect on snacking in the postprandial period may be mediated
via oxytocinergic projections to the brain reward circuit (Melis et al., 2009),
an assumption supported by signs of oxytocin-induced enhancements in the
perceived palatability and sweetness of the moderately appealing snacks
(rice waffles) offered to our obese subjects. The fact that the attenuating
effect of oxytocin on snack intake focused on chocolate cookies, which
were preferentially eaten and rated most palatable, further suggests a strong
rewardrelated component of the observed oxytocin action.
In the obese in contrast to normal-weight subjects, the hypophagic effect
of oxytocin clearly pertained to meal intake in the fasted state, decreasing
calorie consumption from the breakfast buffet by 10 %. The conclusion
that oxytocin elicits stronger effects in obese than normal-weight humans is
supported by findings of more pronounced weight-lowering oxytocin effects
in diet-induced obese compared to control rats, which were associated with
stronger oxytocin-triggered increases in c-Fos expression in the area postrema
and the nucleus of the solitary tract of the hindbrain (Morton et al., 2012).
Moreover, prolonged anorexigenic effects of oxytocin have been reported in
mice kept on a high-fat diet in comparison to control animals (Maejima et al.,
2011). Enhanced oxytocin sensitivity in the obese state has been assumed to
be mediated via improved high-affinity receptor binding of oxytocin due to
elevated cholesterol levels (Ho and Blevins, 2013), and would be in line with
reports that circulating oxytocin concentrations, which were not measured in
the present study, are inversely related to BMI and waist circumference (Qian
et al., 2014). In recent experiments by Lawson et al. (2015) that focused on
oxytocin effects in the fasted state, ad-libitum energy intake was reduced in
both normal- and overweight men. The contrast to our results might stem
from differences in study design including the more pronounced induction of
foodanticipatory processes in the former study (Lawson et al., 2015). Taking
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into account potential rebound effects, our study indicates that the impact of
oxytocin on breakfast intake in obese men is not compensated for by increases
in postprandial thermogenesis and is still evident when subjects are allowed
to snack. In conjunction with our observation that stronger anorexigenic
effects of oxytocin during breakfast are associated with relatively smaller
respective reductions in snack intake, this pattern points to a global, albeit
tightly regulated enhancement of satiety signaling by oxytocin. This effect
is not readily reflected in subjective hunger ratings which accords with the
general treatment unawareness of our subjects. In line with our results, pilot
data suggest that long-term oxytocin administration may support weight loss
in obese patients (Zhang et al., 2013).
The finding of reduced breakfast intake after oxytocin administration in
the fasted state suggests that the peptide restrains hunger-driven, primarily
homeostatically regulated eating, although under normal circumstances in-
gestive behavior triggered by food deprivation also involves a strong hedonic
component. Our analyses did not yield indicators that the inhibitory effect
of oxytocin on breakfast intake in the obese men focused on such hedonic
aspects of food consumption or could be considered a mere consequence of
oxytocin acting on reward processing. Still, in obese compared with normal-
weight individuals, brain reward circuits show greater activation in response
to palatable versus bland foods (Nummenmaa et al., 2012) whereas fronto-
cortical inhibitory control of food intake appears to be reduced (Ziauddeen
et al., 2012). Therefore, the enhanced hypophagic effect of oxytocin in obese
compared with normal-weight subjects may also be interpreted against the
background of a stronger reinforcing quality of food intake and the tendency
to overeat pleasurable food in obesity (Gibson, 2006). In line with this, our
obese subjects consumed ∼240 kcal more than the normal-weight subjects
in the respective placebo conditions. In animal experiments, oxytocin re-
ceptor antagonists acutely attenuate the anorexigenic impact of hormones
like corticotropin-releasing hormone (Olson et al., 1991), whereas alpha-
melanocyte stimulating hormone, a catabolic messenger, triggers oxytocin
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release from supraoptic neurons (Sabatier et al., 2003). Oxytocin might fur-
thermore restrain food intake by acting on downstream mediators of the leptin
signal (Blevins et al., 2004) and enhancing cholecystokinin signaling (Lawson
et al., 2015). Tests of olfactory function in our experiments indicated that
the decrease in food intake most likely was not mediated by direct effects on
sensory processing. Biasing effects on ingestive behavior related to demand
characteristics and social desirability were excluded by respective interviews.
Oxytocin administration did not induce significant alterations in fasting
and postprandial resting energy expenditure. Signs of decreases in the res-
piratory quotient and carbohydrate utilization and respective increases in
fat utilization emerging in the obese subjects during the postprandial period
disappeared after adjustment for preceding calorie intake, suggesting that
they might rather be attributed to oxytocin-induced decreases in macronutri-
ent consumption. In diet-induced obese rats losing weight during systemic
chronic oxytocin administration, the decrease in energy expenditure normally
associated with weight loss was prevented by oxytocin, probably via effects
on hypothalamic thermoregulation (Morton et al., 2012). In obese nonhuman
primates, chronic subcutaneous administration of oxytocin increased energy
expenditure in the dark cycle by 14 % (Blevins et al., 2015). Thus, our find-
ing suggests that rather than exerting acute effects on energy expenditure,
oxytocin contributes to its regulation on a long-term basis, which might turn
out to be a critical factor in future clinical applications. Oxytocin blunted
plasma glucose excursions during the postprandial period in obese as well as
normal-weight subjects. Notably, this effect was still evident after correcting
the data for differences in calorie and carbohydrate intake from the breakfast
buffet, which suggests an oxytocin-induced improvement in insulin sensitivity.
Accordingly, oxytocin enhanced insulin sensitivity and glucose tolerance in
rodent models of diet-induced obesity independent of its effects on body
weight (Morton et al., 2012) and also in rhesus monkeys with diet-induced
obesity (Blevins et al., 2015). In the study by Lawson et al. (2015) intranasal
oxytocin reduced fasting insulin secretion without affecting glucose levels,
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which also implies insulin-sensitizing properties of oxytocin and underlines
that the role of oxytocin in glucose homeostasis in humans is in need of further
investigation. The reduction in HPA axis activity by oxytocin extends previous
findings of an attenuating impact of intranasal oxytocin on cortisol secretion
in response to stress (Cardoso et al., 2013). Acute and chronic activation of
endocrine stress axes facilitates the intake of ‘comfort food,’ that is, highly
palatable food (Dallman et al., 2003). Vice versa, consuming sucrose reduces
HPA axis activity in a negative feedback loop by activation of central nervous
reward circuits (Ulrich-Lai et al., 2010). With regard to the link between emo-
tional regulation and food intake (Gibson, 2006), a mediation of oxytocin’s
attenuating impact on food intake via reductions in HPA axis activity might
be expected to be of particular relevance in obese subjects. However, in our
studies the two phenomena were statistically related only in normal-weight
participants (Ott et al., 2013).
In summary, our study indicates a restraining effect of oxytocin on hunger-
and reward-driven eating behavior in obese humans that goes along with a
suppression of HPA axis activity and signs of enhanced peripheral insulin
sensitivity. In contrast to messengers like insulin and leptin, whose anorex-
igenic impact is blunted when body weight is increased (Begg and Woods,
2013), oxytocin exerts a potent acute inhibition of food intake in obese sub-
jects which even surpasses the effect found in normal-weight humans. These
results clearly warrant further investigations on long-term oxytocin effects in
metabolic disorders.
3 | Study II: Insulin and sleep-
related HPA axis activity
Published as: Thienel, M., Wilhelm, I., Benedict, C., Born, J., and Hallschmid,
M. (2017). Intranasal insulin decreases circulating cortisol concentrations
during early sleep in elderly humans. Neurobiology of Aging, 54:170–4.
3.1 Introduction
The efficient regulation of neuroendocrine stress systems including the HPA
axis is relevant not only with regard to their activation in response to environ-
mental challenges, but also to endogenous circadian rhythms (Buckley and
Schatzberg, 2005). Release of ACTH and cortisol is triggered by CRH and
regulated via glucocorticoid feedback at the hippocampal and hypothalamic
levels. In the first night-half, ACTH and cortisol concentrations reach nadir
values which indicate basal secretory HPA axis activity in the absence of
external stimulation (Kern et al., 1996). Elderly humans display changes
in sleep-related neuroendocrine patterns, in particular a decrease in growth
hormone release and an increase in HPA axis activity, which are paralleled
by a reduction in the amount of time spent in rapid eye-movement (REM)
and slow-wave sleep (Ohayon et al., 2004; Van Cauter et al., 2000). Since
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nocturnal hypercortisolism in aging individuals as a result of weakened central
nervous control of HPA axis activity is assumed to contribute to disorders such
as obesity, depression, and cognitive impairments (McEwen, 2000; Popp et al.,
2015), identifying non-glucocorticoid factors that inhibit HPA axis activity
may contribute to new approaches in the prevention and treatment of these
ailments. Intranasal insulin, which is known to reach the brain compartment
within one hour after administration (Born et al., 2002), has been repeatedly
shown to attenuate HPA axis secretion (Benedict et al., 2004; Böhringer et al.,
2008; Hallschmid et al., 2008). We investigated the effect of intranasal in-
sulin on HPA axis secretion during early sleep in healthy elderly compared
to young subjects. Considering the association between increased age and
nocturnal HPA axis hyperactivity (Van Cauter et al., 2000) as well as impaired
central nervous insulin signaling (Biessels and Reagan, 2015), we expected
an inhibitory effect of insulin on ACTH and cortisol secretion particularly in
elderly subjects.
3.2 Methods
Subjects
Fourteen healthy elderly volunteers (8 men, 6 women; age, mean± SEM,
70.00±0.63years; BMI, 24.83±0.66kg/m2) and 30 healthy young individ-
uals (16 men, 14 women; age, 23.63±0.45years; BMI, 22.93±0.33kg/m2)
participated in, respectively, Experiments I and II. In the young participants,
sleep-related electroencephalographic power spectra and memory perfor-
mance were analyzed in addition and have been reported elsewhere (Feld
et al., 2016). Relevant illness of our subjects was excluded by medical history
and clinical examination. All subjects reported having a regular sleep-wake
cycle and were not on medication except for estrogen-dominant oral con-
traceptives taken by all young women. All subjects spent one night in the
sleep laboratory to adapt to the experimental procedure; visual inspection
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of respective polysomnographical results ensured that none of the subjects
displayed abnormal sleep characteristics. They gave written informed consent
to the study that conformed to the Declaration of Helsinki and was approved
by the local ethics committee.
Study design and procedure
Experiments followed a balanced, placebo-controlled, double-blind, within-
subject, crossover design. All participants took part in two sessions which
were identical except for the administration of insulin or placebo. Sessions
were scheduled to be apart as close to 28 days as possible and the young
women did not participate during their menstruation phases. Subjects were
told to get up around 0700 h and to abstain from naps or caffeine intake on
experimental days, and to follow their usual dinner routines around 1800–
1900 h. Experiments started around 2000 h. Electrodes were attached for
standard polysomnographic recordings including electroencephalogram (at
sites C3 and C4) that were scored offline according to standard criteria as wake,
sleep stages N1, N2, N3, and REM sleep. At 2230 h, subjects were intranasally
administered a total dose of 1.6 ml insulin (160 IU; Insulin Actrapid®; Novo
Nordisk, Mainz, Germany) or vehicle (carrier solution) via sixteen 0.1 ml
puffs (8 per each nostril) in 1-min intervals. Subjects were allowed to sleep
between 2300 h (lights off) and 0700 h (awakening), which corresponded to
the period of polysomnographical recordings.
Blood sampling and control measures
Peripheral blood for the assessment of serum cortisol, C-peptide, insulin, as
well as glucose and plasma ACTH was sampled during a pre-sleep baseline
and at 20- to 40-min intervals during the first night-half until 0320 h (see
Figure 3.1). For the group of elderly subjects, slight adjustments in the blood
sampling schedule were introduced in order to increase the feasibility of
repeated blood sampling and to restrict the burden of experimental participa-
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tion, resulting in minor respective differences to the group of young subjects
outside the main time period of interest (2300–0020 h). Blood was drawn
via long thin tubes enabling blood collection from an adjacent room while
minimizing disruptive effects on the subject’s sleep. Routine assays were used
to determine concentrations of ACTH, cortisol, C-peptide (all Immulite, DPC,
Los Angeles, CA), insulin (Insulin ELISA Kit, Dako, Glostrup, Denmark),
and glucose (HemoCue® Glucose 201 Analyzer, HemoCue AB, Ångelholm,
Sweden).
Appetite, thirst, and sleepiness were self-reported on visual analogue
scales (0–100 mm) in both experiments. Mood, well-being and subjective
sleep quality were assessed via established rating scales, and heart rate and
blood pressure were monitored before and after sleep.
Statistical analyses
For analysis of sleep stages, one female and one male participant of Experi-
ment II were excluded because of data loss. Analyses relied on Greenhouse-
Geisser-corrected analyses of covariance (ANCOVA) for repeated measure-
ments with baseline values as covariates and the between subject-factor ‘sex’
(male/female) and the within-subject factors ‘treatment’ (insulin/placebo) and
‘time.’ Areas under the curve calculated according to the trapezoidal rule and
single time points were compared by t-tests. For comparisons between elderly
and young subjects, linear mixed models were used with the between-subject
factor ‘age’ (elderly/young). In addition, individual slope coefficients were
obtained in the form of beta weights of linear regression lines fitted to ACTH
and cortisol values between 2300–0320 h, and were compared between groups
by two-tailed unpaired t-tests. A P value < 0.05 was considered significant;
data are presented as mean±SEM.
3.3 Results 55
3.3 Results
Increased HPA axis activity during early sleep in elderly compared to
young subjects
Cortisol AUC2300–0320 h values were higher in elderly compared to young
subjects (13,472±584 vs. 11,034±972nmol/L×min, t(41) =−2.22, P =
0.032; t(42) =−0.74, P = 0.463 for respective ACTH values). Accordingly,
the increases in ACTH and cortisol concentrations emerging across the first
night-halves of the respective placebo conditions were stronger in elderly
than young subjects (beta weight means, ACTH, 0.15±0.02 vs. 0.06±0.01,
t(19) =−3.48, P = 0.003; cortisol, 6.81±1.66 vs. 0.64±1.21, t(41) =−2.96,
P = 0.005). Nadir values of ACTH and cortisol did not differ between groups
regarding levels (all P > 0.20) and timing (P > 0.24). Cortisol AUC2300–0320 h
values of the respective placebo conditions were moderately correlated with
BMI in the elderly (r = 0.54, P = 0.048), but not in the young subjects
(r =−0.15,P = 0.43).
Intranasal insulin dampens early-sleep cortisol concentrations in elderly
subjects
Blood parameters did not differ between conditions during baseline (all
P > 0.15). In the elderly subjects, insulin compared to placebo adminis-
tration decreased cortisol concentrations during the first night-half (2300–
0320 h; F(1,10) = 5.83, P = 0.036 for treatment; t(13) = 2.40, P = 0.03 for the
difference in AUC2300–0020 h), whereas this effect was absent in young partic-
ipants (all P > 0.44; F(22,129) = 2.23, P = 0.003 for treatment× time× age;
Figure 3.1a). In the elderly, the insulin-induced decrease in cortisol concen-
trations emerged irrespective of the subjects’ sex (P > 0.32). Its extent was
proportional to the respective cortisol nadir level in the placebo condition
(r = 0.60, P = 0.03, Pearson’s coefficient), but was statistically unrelated to
changes in nocturnal levels of insulin, C-peptide, and glucose (all P > 0.38;
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P > 0.46 for the group of young subjects). Plasma ACTH levels were com-
parable between groups (P = 0.13) and were not influenced by treatment
(both P> 0.56 for treatment; all P> 0.10 for single time point comparisons;
Figure 3.1b).
Serum insulin and blood glucose concentrations
Serum insulin concentrations were not affected by insulin administration in the
elderly subjects (all P> 0.58). In the young participants they rose shortly after
substance administration but were comparable between conditions thereafter
(P> 0.73 for treatment× time; Figure 3.1c, upper lines), with no statistical
differences to the group of elderly subjects (P = 0.24 for age). In both
groups, serum C-peptide concentrations slightly decreased after intranasal
insulin administration (both P < 0.1 for differences at 2320 h), but did not
differ between conditions thereafter (P = 0.68 and P = 0.85, respectively,
for treatment× time; P > 0.62 for age). In accordance with the ephemeral
increase in peripheral insulin concentrations, in the group of young subjects
blood glucose levels were acutely decreased after peptide administration at
2300 h, but subsequently returned to placebo condition values (P = 0.65 for
treatment× time). Across conditions, blood glucose levels were lower in
elderly than young individuals (P < 0.001 for age; Figure 3.1c, lower lines).
Sleep parameters and control measures
Independent of the treatment, elderly in comparison to younger subjects had
longer wake and light sleep (N1) periods at the expense of slow wave (N3)
and REM sleep (F(2,92) = 29.78, P < 0.001 for sleep stage× age; Table 3.1)
assessed across the whole night. Sleepiness ratings and subjective estimations
of sleep onset and sleep quality did not differ between groups (all P> 0.20).
Intranasal insulin compared to placebo generally did not alter sleep latency,
whole-night sleep architecture and total sleep time (all P > 0.29). Early
sleep (2300–0320 h) likewise was unaffected by insulin in the elderly (all
3.3 Results 57
S
er
um
 c
or
tis
ol
 (n
m
ol
/L
)
0
20
40
60
80
100
120
140
160
180
200
S
er
um
 c
or
tis
ol
 (n
m
ol
/L
)
0
20
40
60
80
100
120
140
160
180
200
P
la
sm
a 
A
C
TH
 (p
m
ol
/L
)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
P
la
sm
a 
A
C
TH
 (p
m
ol
/L
)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
Time
S
er
um
 in
su
lin
 (p
m
ol
/L
)
0
20
40
60
80
100
120
140
160
Time
S
er
um
 in
su
lin
 (p
m
ol
/L
)
0
B
lood glucose (m
m
ol/L)0.0
B
lood glucose (m
m
ol/L)0.0
AUC
0
10
20
30
40
4.0
4.5
5.0
5.5
6.0
****
4.0
4.5
5.0
5.5
6.0
**
20
40
60
80
100
120
140
160
**
a
b
c
AUC
0
10
20
30
40
Elderly Young
*
Figure 3.1 Blood parameters. Mean±SEM concentrations of serum corti-
sol (a; inserts depict AUC2300–0020 h values in (nmol/L×min)/100), plasma
ACTH (b), serum insulin and blood glucose (c; upper and lower lines, re-
spectively) measured in elderly (n = 14; left panels) and young participants
(n = 30; right panels) who were intranasally administered insulin (160 IU;
black dots/squares/bars and solid lines) or placebo (white dots/squares/bars
and dotted lines) at 2230 h (dotted line). ∗P < 0.05, ∗∗P < 0.01 for compar-
isons between groups (t-tests).
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P > 0.13) and young subjects (P > 0.20), as was subjective sleep quality
(P> 0.53; Table 3.1). Self-rated mood as well as hunger, thirst, and sleepiness
ratings were not affected by insulin (all P> 0.15; see Table 3.1 for these and
cardiovascular measures). Elderly compared to young subjects showed a trend
towards elevated systolic blood pressure values (P = 0.07 for age). Heart
rate and blood pressure were generally not affected by intranasal insulin (all
P> 0.18).
3.4 Discussion
We demonstrate that intranasal insulin, which has been shown to reach the
brain compartment (Born et al., 2002) and elicit functional brain effects
(Hallschmid et al., 2004b) within one hour after administration, reduces
circulating concentrations of cortisol during the first night-half in elderly
subjects. This result is in accordance with reports by our and other groups that
intranasal insulin attenuates HPA axis activity in young men after long-term
treatment (Benedict et al., 2004) and when administered before a social stress
test (Böhringer et al., 2008). Physiologically, circulating insulin reaches the
CNS via a receptor-mediated saturable transport across the blood-brain barrier
and might dampen HPA axis secretion by acting on hypothalamic nuclei
and limbic structures like the hippocampal formation, which express large
numbers of insulin receptors (Plum et al., 2005). In contrast, euglycemic
hyperinsulinemic clamps rather increase HPA axis secretion (Fruehwald-
Schultes et al., 1999), probably by boosting hormone synthesis in the adrenal
cortex that is not effectively reached by intranasal insulin. In comparison to
their young controls, our elderly participants displayed increased secretory
HPA axis activity as well as an increased amount of time spent awake and
in sleep stage 1, but a decreased duration of REM sleep and sleep stage 3,
indicators of decaying sleep quantity and quality generally associated with
aging (Van Cauter et al., 2000). Intranasal insulin did not induce significant
changes in sleep architecture, which is in line with the lack of respective
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Table 3.1 (Previous page.) Mean±SEM total sleep time and time spent in
different sleep stages (relative to total sleep period) are indicated for both
experimental nights (2300–0700 h). Psychological and physiological control
variables were obtained before and after sleep. Subjective sleep quality
was assessed by 4-point scale checklists including seven adjectives (e.g.,
‘calm,’ ‘relaxed’), and the average score was calculated. Appetite, thirst, and
sleepiness were rated on visual analogue scales (0–100 mm) anchored at ‘not
at all’ and ‘extreme.’ Mood and well-being were assessed on 5-point scales.
BP, blood pressure (mmHg). P values derive from comparisons between
conditions (t-tests) and group ANOVA main effects; elderly subjects, n = 14;
young subjects, n = 28.
effects of peripheral hyperinsulinemia (Sturis et al., 1995). Although these
observations suggest that insulin per se does not induce robust changes in
sleep architecture, it cannot be excluded that higher doses of insulin or longer
administration periods are necessary to modulate sleep quantity and quality in
humans (Hallschmid et al., 2008; see Feld et al., 2016 for effects of intranasal
insulin on electroencephalographic power spectra).
Intranasal insulin delivery reduced early-sleep cortisol concentrations in
elderly but not in young participants. Importantly, sleepiness and subjectively
experienced sleep onset and quality were comparable between groups, ruling
out acute differences in psychological stress levels as mediators of the ob-
served age-specific insulin effect. It is also unlikely that the small amount of
intranasal insulin reaching the blood stream via spillover and causing a short
drop in plasma glucose levels masked a centrally inhibiting insulin effect in the
younger subjects by stimulating cortisol release. Spillover-induced increases
in circulating insulin concentrations are negligible (Ott et al., 2015) compared
to elevations needed to stimulate HPA axis activity under euglycemic con-
ditions (Fruehwald-Schultes et al., 1999). Moreover, blood glucose levels
remained clearly above the hypoglycemic threshold of 3.6–3.8 mmol/L where
hormonal counter-regulation sets in. The fact that changes in cortisol were
generally unrelated to parameters of peripheral glucose homeostasis points to
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a central nervous mediation of insulin’s suppressive effect on sleep-related
cortisol concentrations in elderly subjects. We were not able to detect treat-
ment effects on ACTH concentrations in the present study, so that an ACTH
independent mechanism of adrenal regulation may also be involved (Bornstein
et al., 2008). This question clearly is in need of further clarification.
Our finding of an insulin effect in the elderly but not young subjects fits
with previous studies indicating that in young, healthy men, attenuating effects
of intranasal insulin on basal HPA axis activity only emerge after long-term
administration (Benedict et al., 2004). Acutely attenuating effects of intranasal
insulin on basal cortisol concentrations during wakefulness were found in
obese (Hallschmid et al., 2008), but not in normal-weight men (Benedict et al.,
2004). Obesity is associated with and also appears to be promoted by excessive
HPA axis secretion, e.g., due to chronic stress (Incollingo Rodriguez et al.,
2015). Normal aging likewise goes along with alterations in the regulation
of the HPA system, in particular increased nocturnal cortisol secretion (Van
Cauter et al., 2000). In our sample of elderly subjects, BMI was positively
related to serum cortisol concentrations during the first night-half. In general,
however, the elderly participants of the present study displayed a high level of
physical health and only moderate signs of nocturnal HPA axis up-regulation,
which might explain the relative subtlety of the observed insulin effect. Still,
the extent of insulin-induced cortisol reductions was associated with the
height of respective cortisol nadir levels. Therefore, inhibitory effects of
insulin on HPA axis secretory activity are expected to be stronger in aging
subjects who show weaker nocturnal stress axis inhibition. In these subjects,
intranasal insulin may be a helpful means to normalize nocturnal HPA axis
activity and improve sleep-associated endocrine regulation. It remains to
be seen if intensified or prolonged insulin administration paradigms may
moreover induce associated changes in sleep parameters and, in this way,
potentiate the beneficial metabolic and cognitive impact of central nervous
insulin administration (Spetter and Hallschmid, 2015).

4 | Study III: Orexin A and
glucose homeostasis
Thienel, M., Elsässer, T., Lamprinou, A., Klement, J., Peter, A., and
Hallschmid, M. (2017). Intranasal orexin A acutely improves glucose toler-
ance in healthy men. in preparation
4.1 Introduction
Orexin A (hypocretin-1) is an excitatory hypothalamic neuropeptide that
exerts multifaceted effects in the brain and the body periphery, which up
to now have been primarily investigated in animal experiments. Orexin A
neurons are bilaterally distributed within the lateral hypothalamic area and
adjacent regions and project widely to brain regions regulating autonomic
functions, feeding, and sleep (e.g., cerebral cortex, hippocampus, amygdala,
locus coeruleus, and raphe nuclei; Kukkonen et al. (2002); Nambu et al.
(1999)). Patients with narcolepsy with cataplexy, a neurological disorder
characterized by transient episodes of excessive daytime sleepiness and muscle
weakness, show a selective loss of hypothalamic orexin A-containing neurons
(Thannickal et al., 2000) and blunted orexin A levels in the CSF (Nishino
et al., 2000). In animal studies, orexin A has been shown to increase food
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intake and body weight (Edwards et al., 1999) probably through inhibition of
anorexigenic POMC neurons and simultaneous stimulation of NPY neurons in
the nucleus arcuatus of the hypothalamus (Muroya et al., 2004). This pattern
suggests that orexin A is essential not only for maintaining a normal sleep-
wake cycle but also affects energy homeostasis and metabolism (Sutcliffe and
de Lecea, 2000).
The expression of orexin A receptors in the pancreas and the intestinal
mucosa (Ehrström et al., 2005) has led to the assumption that orexin A might
contribute to the regulation of intestinal glucose uptake and insulin-dependent
glucose utilization (Ducroc et al., 2007). In rats, intraperitoneal administration
of orexin A reduces plasma glucose levels during an OGTT probably by
influencing intestinal glucose uptake (Ducroc et al., 2007). Moreover, it
was demonstrated in rats that insulin-dependent muscle glucose uptake is
increased by hypothalamic orexin A administration through activation of the
sympathetic nervous system and β2-adrenergic signaling pathways (Shiuchi
et al., 2009). In the present study, we investigated the effect of orexin A on
glucoregulation assessed by means of an OGTT in healthy young men with
NGT. Orexin A was administered via the intranasal pathway that is known
to enable substances like neuropeptides to travel to the brain compartment in
animals (Dhuria et al., 2009) and humans (Born et al., 2002). Assuming an
improving effect of orexin A on insulin sensitivity, we expected an inhibitory
effect of orexin A administration on blood glucose and insulin concentrations.
4.2 Methods
Subjects
Nineteen healthy normal-weight men were recruited on site via the univer-
sity’s mailing lists. All relevant illness was excluded by medical history and
clinical examination taking place before the first experimental session. Body
composition assessed by bioelectrical impedance analyses (Nutriguard-M,
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Data Input, Germany) was performed at the start of each experimental session
(see Table 4.1 for subject characteristics). Participants gave written informed
consent to the study that conformed to the Declaration of Helsinki and was
approved by the local ethics committee.
Table 4.1 Subject characteristics.
Variable Mean±SEM
Age (years) 22.89±0.63
Body weight (kg) 71.43±1.24
BMI (kg/m2) 22.47±0.33
HbA1c (mmol/mol) 33.11±0.76
HbA1c (%) 5.17±0.07
Lean body mass (kg) 61.36±1.28
Body fat mass (kg) 10.35±0.62
Body fat mass (% of total weight) 14.43±0.84
Body cell mass (% of lean body mass) 57.17±0.63
Body water (liters) 44.92±0.93
Phase angle (°) 7.21±0.15
PFS (total scale score) 2.80±0.14
Mean±SEM values are indicated. Body composition was measured by bio-
electrical impedance analysis (Nutriguard-M, Data Input, Germany) in a
clinical examination taking place shortly before each experimental session.
PFS, total scale score of the Power of Food Scale (PFS), a measure of propen-
sity to consume palatable foods, assessed before substance administration and
averaged across conditions; n = 19.
Experimental procedure
Experiments were carried out in a balanced, double-blind, cross-over, within-
subject comparison. Each subject participated in two experimental sessions
(orexin A and placebo) spaced at least 14 days apart. Participants were in-
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structed to abstain from the intake of food and caffeinated and alcoholic
beverages after 2000 h on the day preceding each session.
After the subject’s arrival at the laboratory at ∼0800 h, baseline vigilance
was tested (see Figure 4.1 for the experimental procedure). A venous cannula
was inserted into the subject’s nondominant arm to enable drawing of venous
blood. Thereafter, blood was sampled for baseline assessments of hormonal
parameters. At 0915 h each subject was intranasally administered 500 nmol
orexin A (1.781 mg of C152H243N47O44S4 acetate salt; Bachem, Bubendorf,
Switzerland; soluted in 2.3 ml water for injection) or placebo (water for in-
jection) at 20 individual 0.1 ml-puffs (10 per alternating nostril) with 1-min
intervals in-between. After intranasal administration, neuropeptides reach
the central nervous compartment within ∼45 min (Born et al., 2002). Tim-
ing and dosing were further based on previous experiments on intranasal
orexin A in humans (Baier et al., 2011, 2008; Weinhold et al., 2014) and
animals (Deadwyler et al., 2007). At 1000 h an OGTT (300 ml Accu-Check
Dextrose O.G.T. solution containing 75 g anhydrous glucose) was performed
with venous blood samples taken at 0, 10, 20, 30, 60, 90, and 120 minutes for
the measurement of plasma glucose, serum insulin, and serum C-peptide con-
centrations. After the OGTT, from 1305–1330 h, participants were presented
with a lunch consisting of a conventional pizza margherita (300 g; energy
value: 217 kcal per 100 g; 32.3 g carbohydrates per 100 g; 8.7 g proteins per
100 g; 5.4 g fat per 100 g). Casual snack intake was assessed 5 min thereafter
under the pretext of a snack taste test. Throughout the experiment, feelings
of hunger, mood, and subjective well-being were repeatedly rated on visual
analogue scales (0–100 mm) and energy expenditure was assessed by indirect
calorimetry before and after substance administration. Vigilance as well as
heart rate and blood pressure were monitored throughout the experiment. At
the end of experiments, subjects were asked to indicate their account of the
study purpose and if they thought to have received orexin A or placebo.
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Measurement of plasma glucose, hormonal parameters, and energy ex-
penditure
Blood samples to assess serum insulin, C-peptide, cortisol, and growth hor-
mone, as well as plasma glucose, lactate, ACTH, and NEFA were centrifuged,
and samples were stored at −80 ◦C. Concentrations of glucose and lactate in
fluoride plasma were determined with the ADVIA® Chemistry XPT clinical
chemistry analyzer according to the hexokinase and colorimetric lactatoxidase
method, respectively. Serum insulin, C-peptide, and cortisol concentrations
were measured with the ADVIA® Centaur XPT immunology analyzer and
concentrations of growth hormone and ACTH were measured using the Im-
mulite® 2000 XPi Immunoassay-System. Plasma NEFA were determined
according to the ACS-ACOD method (NEFA-HR(2), Wako Chemicals GmbH,
Neuss, Germany) with the ADVIA® Chemistry XPT clinical chemistry ana-
lyzer (all instruments form Siemens Healthcare Diagnostics, Eschborn, Ger-
many).
Resting energy expenditure (expressed as kcal/day) and the respiratory
quotient were measured via indirect calorimetry using a DeltaTrac II venti-
lated-hood system (SensorMedics Vmax 29n; VIASYS® Healthcare, Yorba
Linda, CA, USA). Before each use, the device was calibrated with calibration
gas to 5 % CO2 and 95 % O2. Calorimetric measurements (30 min each) took
place at 0840 h (baseline) and immediately after onset of OGTT at 1005 h.
Assessments of hunger, thirst, food craving, mood, and vigilance
Hunger, thirst, and food craving were rated on visual analog scale (0–100 mm).
Self-reported mood was assessed on 5-point scales covering the categories
good/bad mood, alertness/sleepiness and calmness/agitation (MDBF; Steyer
et al., 1997). For the examination of vigilance, subjects performed a simple
5-min PC-based task (Diekelmann et al., 2011) before and after substance
administration. In this 5-min task, a red dot appeared at random intervals
either on the left or the right side of the screen, and subjects were required to
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press the respective key as fast as possible, receiving immediate feedback in
the form of the reaction time for correct responses or an error message. Mean
reaction time was registered and adjusted for mistakes by adding the square
root of the product of the mean reaction time and the number of mistakes.
Reward-driven food intake
Reward-related eating in the relative absence of hunger was assessed under
the pretext of a taste test (Hallschmid et al., 2012; Higgs et al., 2008; Ott et al.,
2013) that included snacks of three different types, i.e., salt crackers, rice
waffles, and chocolate cookies, respectively, but comparable calorie content
and macronutrient composition (Ott et al., 2013). Participants were instructed
to taste and rate each snack type on a VAS anchored by 0 (not at all) and
100 mm (very palatable/sweet/salty/sour). Subjects were informed that they
could eat as many snacks as they liked, and were left alone for 10 min. Intake
was covertly measured by weighing the snacks before and after the test.
Statistical analyses
For the analyses of blood parameters and vigilance, respectively, one par-
ticipant was excluded because of data loss. Analyses were generally based
on ANOVA with the within-subject factors ‘treatment’ (orexin A/placebo),
‘time’, ‘snack type’ (salty/sweet/bland), and ‘taste’ (salty/sweet/sour) as ap-
propriate. Degrees of freedom were corrected using the Greenhouse-Geisser
procedure. Areas under the curve were calculated according to the trapezoidal
rule covering the relevant time periods. Significant ANOVA and AUC effects
were specified by two-sided pairwise t-tests. For blood parameters, baseline
adjustment was achieved by subtracting individual baseline values from in-
dividual post-intervention measurements. Insulin sensitivity indexes were
calculated according to the respective formulas given in Otten et al. (2014).
All data are presented as means±SEM. A P value < 0.05 was considered
significant.
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4.3 Results
Orexin A improves glucose homeostasis
Baseline concentrations of glucose, insulin and C-peptide were comparable
between conditions (P > 0.2 for all comparisons). Subjects did not differ
in their fasting insulin sensitivity across conditions reflected in HOMA-IR
indices (placebo, 1.29±0.15; orexin A, 1.13±0.13; P = 0.39). During the
2 h OGTT, plasma glucose excursions were blunted by orexin A compared to
placebo administration (F(1,16) = 6.22; P = 0.02 for treatment; Figure 4.2a),
especially in the first 60 min (P = 0.007 for AUC1000–1100 h). Serum insulin
levels were moderately increased after orexin A compared to placebo admin-
istration 5 min after the glucose load (P = 0.063), with a subsequent slight
attenuation at 10 min (P = 0.073) and 30 min thereafter (P = 0.049); Fig-
ure 4.2b). Accordingly, Cederholm insulin sensitivity index values calculated
from glucose and insulin excursions were significantly increased (placebo,
65.43±3.95; orexin A, 71.16±3.98; P = 0.03). C-peptide excursions in gen-
eral matched insulin concentrations, with an immediate attenuation (P = 0.04
and P = 0.048, respectively) after glucose load in the orexin A compared to
placebo condition (Figure 4.2c). The orexin A-induced changes in insulin con-
centrations between the first 60 min of the OGTT were statistically unrelated
to the respective decrease in plasma glucose AUC1000–1100 h values (r = 0.35;
P = 0.16, Pearson’s coefficient).
ACTH, cortisol, lactate, growth hormone, and NEFA
Baseline concentrations of ACTH, cortisol, lactate, growth hormone, and
NEFA did not differ between conditions (all P > 0.4). Orexin A treatment
increased ACTH concentrations acutely after peptide administration at 0925 h
(P = 0.009; Figure 4.2e) and increased cortisol secretion thereafter at 1000 h
(P = 0.009) and 1130 h (P = 0.088; Figure 4.2f). These effects however were
not substantiated by analyses covering the whole experimental period (both
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Figure 4.2 (Previous page.) Mean±SEM concentrations of plasma glucose
(a), serum insulin (b), serum C-peptide (c), plasma lactate (d), plasma ACTH
(e), serum cortisol (f), serum growth hormone (g), and plasma NEFA (h)
assessed before (averaged across the 0845 h and 0900 h baseline values) and
after intranasal administration (vertical dotted line) of orexin A (500 nmol;
black circles and solid lines) and placebo (aqua; white circles and dotted
lines) in healthy men (n = 18). Subjects underwent an oral glucose tolerance
test (OGTT solution containing 75 g glucose) from 1000–1200 h (grey boxes).
Mean baseline values of both conditions are averaged to a common baseline.
∗∗P< 0.01, ∗P< 0.05, tP< 0.1 for comparisons between conditions (pairwise
t-tests).
P > 0.27 for treatment× time) and by ANOVA and AUC analyses focusing
on the time period during the OGTT (all P > 0.16). The differences in ACTH
and cortisol concentrations between conditions after peptide administration
were statistically unrelated to the orexin A-induced blunting of the glucose
response (AUC1000–1100 h; r = 0.21, P = 0.41; r = 0.4, P = 0.12, respectively;
Pearson’s coefficients).
Besides a general reduction in lactate concentrations in the orexin A
compared to the placebo condition during the whole experimental time af-
ter glucose load (AUC1000–1300 h, t(17) = −2.38, P = 0.03; F(1,17) = 4.57,
P = 0.047 for treatment), participants’ individual peaks in lactate concentra-
tions were significantly reduced after peptide administration (1.61±0.08 vs.
1.41±0.05; t(17) =−2.25, P = 0.038; Figure 4.2d). The orexin A-induced
reductions in lactate peak levels were significantly correlated to the respective
decrease in glucose response (AUC1000–1100 h; r = 0.55, P = 0.019).
Growth hormone and NEFA concentrations did not indicate effects of
orexin A during the experimental period (P = 0.57 and P = 0.49, respectively,
for treatment× time; Figure 4.2g-h).
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Heart rate, and blood pressure, and energy expenditure
Heart rate was unaffected by substance administration throughout the experi-
ment (all P > 0.4; Figure 4.3a). Systolic blood pressure was slightly elevated
in the orexin A compared to the placebo condition acutely after peptide ad-
ministration at 0925 h (placebo, 122± 2mmHg; orexin A, 127± 2mmHg,
P = 0.062), but comparable apart from that (all P > 0.35 for treatment× time
and single time-point comparisons; Figure 4.3b). Diastolic blood pressure
was blunted in the orexin A condition during OGTT at 1030 h (placebo,
73± 1mmHg; orexin A, 69± 1mmHg, P = 0.022) and slightly thereafter
at 1230 h (placebo, 75± 1mmHg; orexin A, 72± 2mmHg, P = 0.058; Fig-
ure 4.3c). Energy expenditure assessed by indirect calorimetry was com-
parable between conditions both at baseline (placebo, 1709± 51kcal/day;
orexin A, 1667± 40kcal/day, P > 0.45) and after glucose intake (placebo,
1773±48kcal/day; orexin A, 1800±50kcal/day, P > 0.58; Figure 4.3d).
Orexin A increases food craving but does not influence reward-driven
food intake
Across conditions, hunger and thirst ratings were comparable at baseline (both
P > 0.9) and generally unaltered by orexin A (all P > 0.35 for respective
interactions). However, ratings of food craving were significantly increased
in the orexin A compared to the placebo condition (F(1,18) = 7.28, P = 0.015
for treatment), falling to comparable low values after meal intake at 1330 h
(P = 0.49 for single time point comparison; Figure 4.3f). Snack intake during
the postprandial period was not affected by orexin A (P < 0.43 for treatment;
Figure 4.3e). Orexin A increased the perceived saltiness of salt crackers
(placebo, 7.58±0.18; orexin A, 8.17±0.21; P < 0.05).
Psychological parameters and vigilance
Mood and subjective well-being according to the self-rated categories good/-
bad mood (P > 0.6) and calmness/agitation (P > 0.2) were not affected by
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Figure 4.3 (Previous page.) Upper panels indicate mean±SEM heart rate (a),
systolic (b) and diastolic blood pressure (c) assessed before and after intranasal
administration (vertical dotted line) of orexin A (500 nmol; black circles and
solid lines) and placebo (aqua; white circles and dotted lines). Lower panels
depict resting energy expenditure during the baseline (0840–0910 h) and post-
treatment (1005–1035 h; d), and cumulative snack intake (e) in the placebo
(white bars) and the orexin A condition (black bars). Mean± SEM food
craving according to visual analogue scales (f) and alertness according to the
self-rated mood questionnaire (g) assessed during the whole experimental
period is indicated. ∗∗P < 0.01, ∗P < 0.05, tP < 0.1 for comparisons between
conditions (pairwise t-tests, n = 19).
orexin A, while subjects were more alert in the placebo condition compared
to orexin A (F(3,60) = 3.92; P = 0.01 for treatment× time; Figure 4.3g).
Reaction time was not affected by orexin A (all P > 0.22 for respective
comparisons).
4.4 Discussion
We show an acutely enhancing effect of orexin A administration on glucose
tolerance in healthy men. In fasted subjects undergoing an oral glucose
tolerance test after intranasal orexin A administration, we found that orexin A
attenuates the glucose peak response to a glucose challenge. This effect
was accompanied by an initial trendwise increase in insulin concentrations,
but a decreased response of insulin and C-peptide during the first thirty
minutes after glucose load. Orexin A also attenuated lactate excursions
throughout the whole experimental period and acutely increased ACTH and
cortisol secretion, but did not affect levels of growth hormone and NEFA.
Enhanced glucose tolerance was reflected by an orexin A-induced increase
in the Cederholm index, an indicator for peripheral insulin sensitivity and
glucose uptake into skeletal muscle (Cederholm and Wibell, 1990). Intranasal
orexin A administration also increased perceived craving for food and slightly
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elevated systolic blood pressure, while diastolic blood pressure and alertness
were attenuated.
Our results of an acute stimulatory effect of orexin A on glucose tolerance
extend previous experiments in animals to the human setting (Tsuneki et al.,
2012). The methodological approach of OGTT served as a standardized
measure of insulin resistance and revealed the contribution of orexin A to
glucose homeostasis in humans. In rats exposed to an OGTT following an
overnight fast, blood glucose levels were decreased by pre-treatment with
55 µg/kg intraperitoneal orexin A, effects mediated via an inhibition of in-
testinal glucose absorption that was dependent on the glucose transporter
protein SGLT1 (Ducroc et al., 2007). Injection of 5 pmol orexin A into the
ventromedial nucleus of the hypothalamus in rodents led to enhanced glucose
uptake and glycogen synthesis in skeletal muscle by activation of the sym-
pathetic nervous system and β2-adrenergic signaling (Shiuchi et al., 2009).
Hypothalamic orexin expression in normal and obese mice negatively corre-
lates with changes in blood glucose (Yamanaka et al., 2003). Accordingly,
hypoglycemia upregulates prepro-orexin (Sakurai et al., 1998) and orexin
mRNA (Griffond et al., 1999) and leads to an activation of orexin-containing
neurons in the endocrine pancreas at a peripheral level (Ouedraogo et al.,
2003).
Lactate concentrations were reduced by orexin A throughout the experi-
ment. Lactate, as a critical energy substrate, is supposed to regulate the orexin
system depending on its extracellular concentration (Parsons and Hirasawa,
2010). Due to relatively high blood glucose concentrations during OGTT,
intranasal orexin A administration may have improved the conversion of lac-
tate to glucose via hepatic gluconeogenesis. Notably, orexin receptor type 1
(OX1R)-deficient mice on high-fat diet show improved glycemic regulation
and insulin sensitivity (Funato et al., 2009) and intraperitoneal administration
of OX1R antagonist reduces food intake, body weight gain, fasting blood
glucose levels and plasma insulin levels, while normalizing the increased
metabolic rate in genetically obese mice (Haynes et al., 2002). Therefore,
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improved hyperglycemia and hyperinsulinemia in mice with diet-induced
obesity following a continuous ICV administration of orexin A (0.5 nmol/day;
Ramadori et al., 2011) maybe attributed to an OX2R-dependent mechanism
(Haynes et al., 2002).
In our study, insulin concentrations first showed signs of a swifter increase
after orexin A administration directly followed by an attenuation, which is
partially in line with reports of a stimulatory impact of orexin A on insulin
secretion in animals under non-fasting conditions (Nowak et al., 2000) and
after an intraperitoneal glucose tolerance test (Park et al., 2015). In vitro, con-
versely, orexin A significantly decreases glucose-stimulated insulin secretion
in isolated rat islets (Ouedraogo et al., 2003). However, the observed acute
insulin response and blunted glucose excursion in the present study were
statistically unrelated. In consideration of differential experimental conditions
and the lack of evidence in a human study context, the influence of orexin A
on insulin secretion is in need of further investigation.
Orexin A acutely increased plasma ACTH and serum cortisol levels, which
accords with previous experiments in rodents showing that ICV administration
of orexin A activates the HPA axis (Al-Barazanji et al., 2001; Sakamoto et al.,
2004). Orexin A increases cortisol secretion from human adrenocortical cells
in vitro (Mazzocchi et al., 2001) and orexin neuron activity is conversely
increased by psychological stressors (Chang et al., 2007; Furlong et al., 2009).
Accordingly, orexin A is involved in the regulation of cardiovascular functions
by increasing sympathetic nerve activity in terms of a defence response con-
comitant with high vigilance (Sakurai, 2014b; Samson et al., 1999; Shirasaka
et al., 1999), which is also reflected in our results of slightly elevated sys-
tolic blood pressure levels right after peptide administration. In contrast, our
subjects self-reported less alertness and displayed decreased diastolic blood
pressure in the orexin A condition compared to placebo. Studies in rodents
show that microinjections of low doses of orexin A and orexin B in the nu-
cleus of the solitary tract can also stimulate parasympathetic activity (Ciriello
et al., 2013; de Oliveira et al., 2003; Shih and Chuang, 2007). Against this
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background, our results may be interpreted to indicate a time-dependent effect
of intranasal orexin A on sympathetic activity and vigilance, i.e., initially
increasing HPA axis activity and blood pressure with a subsequent drop in
alertness.
In our study, intranasal administration of orexin A significantly increased
the craving for food, which is in line with results from previous studies
showing an orexigenic effect of ICV administration of orexin A and orexin B
in several species (Sakurai, 2007). Although orexin neurons send excitatory
projections to the VTA and therefore are tightly involved in the modulation
of reward-related processes (Harris et al., 2005; Sakurai, 2014b), orexin A
administration did not significantly increase reward-driven food intake in
the snack test. The uptake of glucose and the standardized meal beforehand
could have masked the expected effect on hedonic food intake. Orexin A
also did not alter resting energy expenditure in our sample of healthy men.
Central infusion of orexin A in rodents repeatedly resulted in increased body
temperature and energy expenditure (Mavanji et al., 2015; Messina et al.,
2014) clearly indicating a link between the peptide and thermoregulation.
Taking into account the role of orexin A in basal sympathetic activation
(Messina et al., 2014), the postprandial rise in energy expenditure following
the glucose load may have blurred the impact of orexin A via ceiling effects.
In sum, our data indicate an improvement in glucose tolerance in healthy
men after intranasal orexin A administration, buttressing the assumption
that orexin A plays a role in blood glucose homeostasis. Considering that
hyperglycemia and insulin resistance are core symptoms of type 2 diabetes
and that no severe side effects of intranasal orexin A administration have
been reported as yet—albeit in a very limited number of studies in humans
(Baier et al., 2011, 2008; Weinhold et al., 2014)—, our preclinical data in
healthy men may bode well for future pharmacological approaches that target
the orexin system. Still, the mechanisms underlying our observations should
be investigated in further studies in humans, which may help delineate the
potential of orexin A in the treatment of metabolic ailments.
5 | Conclusions and general
discussion
The aim of the studies presented in this thesis was to scrutinize specific roles of
central insulin, orexin A, and oxytocin in metabolic control in healthy humans.
Metabolic disorders and obesity are on the rise and represent a worldwide
health concern tied to enormous medical costs (Cawley and Meyerhoefer,
2012; Wang et al., 2011). The growing number of molecules known to
be implicated in energy homeostasis raises nearly limitless possibilities for
an auxiliary medical approach in the treatment of obesity and associated
metabolic disorders. Biologically occurring peptides, such as insulin, orexin A,
and oxytocin may hold some potential as future therapeutics due to good
efficacy, safety, tolerability as well as high selectivity and potency (Fosgerau
and Hoffmann, 2015).
Together, the findings in the studies conducted in this thesis indicate that
the intranasally administered neuropeptides oxytocin, insulin, and orexin A
target pivotal determinants in the development of metabolic disorders, such
as body weight, HPA axis activity, and insulin sensitivity. Oxytocin exerted
an acutely inhibitory impact on food intake that was enhanced rather than
decreased in obese compared with normal-weight men, dampened HPA axis
activity, and blunted postprandial glucose levels in both groups of subjects,
suggesting an oxytocin-induced improvement in insulin sensitivity (Study I).
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In Study II it was found that intranasally administered insulin compared to
placebo reduced serum cortisol levels during early sleep (between 2300 h
and 0020 h) in elderly, but not in young participants indicating that central
insulin acts as an inhibitory signal in the regulation of basal HPA axis activity
and suggesting that improving brain insulin signaling could normalize nadir
stress axis activity in older age. Finally, orexin A attenuated plasma glucose
and lactate peak levels and blunted the early rises in insulin and C-peptide
concentrations during an oral glucose tolerance test in healthy normal-weight
humans, which indicates an essential contribution of orexin A to human
glucose metabolism (Study III).
5.1 Interplay of oxytocin, orexin A, and insulin
in glucose metabolism
Considering the results shown in the present thesis, the effects of IN oxytocin
and orexin A seem to converge in their role in glycemic control and their
insulin-sensitizing properties, respectively. Maintaining glucose homeostasis
is essential for daily functioning and thus for survival. Perturbation in glucose
homeoastasis and insulin action may lead to severe medical conditions, in-
cluding type 2 diabetes and obesity. The mechanisms behind the effects of
orexin A and oxytocin in glycemic control and on pancreatic insulin secretion,
respectively, are still in need of investigation. Both orexin neurons in the LHA
and magnocellular oxytocin neurons in the SON have been found to serve as
glucose sensors (Moriguchi et al., 1999; Song et al., 2014). Orexin neurons
are glucose-inhibited relative to intracelluar energy levels (Venner et al., 2011),
whereas oxytocin neurons are glucose-excited (Song et al., 2014) according
to their respective anabolic/orexigenic and catabolic/anorexigenic properties.
Furthermore, both orexin neurons in the LHA and oxytocin neurons in the
PVN may be important targets for the SCN control of glucose metabolism
(Foppen et al., 2016).
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As evidenced by immunohistochemical methods, OX1R as well as OXTR
are localized in rat pancreatic α- and β-cells (Kirchgessner and Liu, 1999;
Ouedraogo et al., 2003; Suzuki et al., 2013) suggesting that both orexin A and
oxytocin are involved in the release of insulin as well as glucagon. However,
the question whether central or peripheral mechanisms are more or less
involved when it comes to the role of orexin A and oxytocin in glucose
homeostasis remains unclear (Björkstrand et al., 1996; Nowak et al., 2000).
5.1.1 Opposing effects on glucose homeostasis
In vitro, orexin A significantly decreases glucose-stimulated insulin secre-
tion and stimulates glucagon release in low glucose concentration in isolated
rat islets (Ouedraogo et al., 2003). Conversely, Nowak et al. (2005) have
shown that orexin A dose-dependently stimulates insulin secretion at basal
(6.66 mmol/L) and high glucose (26.4 mmol/L) concentrations in the isolated
perfused pancreas. In vivo, subcutaneous (SC) and ICV injection of orexin A
significantly increases circulating insulin and glucose concentrations rats un-
der non-fasting conditions (Nowak et al., 2000). Continuous ICV infusion into
rats fasted for 5 h results in an increase in plasma glucose levels and prevents
the daytime decrease of endogenous glucose production in the liver (Yi et al.,
2009). On the contrary, IV and ICV administration of orexin A causes a
reduction of fasting blood glucose levels in normal mice and streptozotocin-
induced diabetic mice without affecting serum insulin concentrations, whereas
these effects can not be observed under fed conditions (Tsuneki et al., 2002).
Similarly, pre-treatment with intraperitoneal injection of orexin A decreases
blood glucose levels in OGTT using rats fasted overnight (Ducroc et al., 2007)
which is in line with the results presented in Study III. Against this back-
ground, orexin A may affect glucose homeostasis by regulating pancreatic
hormone secretion, although a direct peripheral effect of IN orexin A seems
questionable, not least because after IN administration, peripheral orexin A
concentrations are not significantly increased (Dhuria et al., 2009). The ob-
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served discrepancies in the results suggest that counterregulatory response
might be modulated by glucose availability and metabolic state on the one
hand and some still unknown factors on the other. Thus, no clear role for
orexin A in the regulation of glucose metabolism can be established yet.
Concerning the effect of oxytocin on glucose homeostasis, a similar pat-
tern can be observed. There is evidence of both acute stimulatory and in-
hibitory impacts of oxytocin on insulin secretion and glucose utilization,
respectively, in animals and humans. Intravenous administration of oxytocin
increases insulin secretion in response to intravenously administered glucose
in men (Chiodera et al., 1984). Oxytocin given intranasally in dogs (Altszuler
and Hampshire, 1981) as well as subcutaneously and intracerebroventricularly
in rats (Björkstrand et al., 1996) causes a significant rise not only of insulin but
also of glucagon and glucose levels. However, ICV oxytocin administration
in prediabetic mice on high-fat diet reduces fasting insulin as well as glucose
levels during a glucose tolerance test, whereas streptozotocin-induced diabetic
mice show an increase in fasting insulin secretion (Zhang et al., 2013). How-
ever, Lawson et al. (2015) report a decrease in fasting insulin serum levels
60 min after IN oxytocin administration without affecting glucose levels. In
contrast but in accordance with the results of Study I, IN oxytocin adminis-
tered before a meal reduces postprandial peaks in plasma glucose excursion in
healthy normal-weight men, while insulin secretion is not significantly altered
(Ott et al., 2013). Similarly, IN oxytocin blunts plasma glucose peak response
and increases the early response in insulin concentrations during an OGTT
in healthy men (Klement et al., 2017). In nonhuman primates, chronic SC
oxytocin administration twice a day does not change fasting plasma insulin
levels but significantly lowers glucose levels after 4 weeks of continuous ad-
ministration (Blevins et al., 2015). Taken together, the short- and long-term
effects of oxytocin on glucose homeostasis seem to depend on different factors,
including route of administration and subject’s metabolic state. Considering
the rapid and sustained increase in plasma oxytocin concentrations following
its intranasal delivery (Klement et al., 2017; Striepens et al., 2013), it can be
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assumed that IN oxytocin might exert effects on glucose levels, as shown in
Study I, at least partly via direct, peripheral action. Possibly preautonomic
oxytocin neurons projecting to the liver are most likely primarily involved,
instead of those projecting to the pancreas (Buijs et al., 2001; O’Hare and
Zsombok, 2016).
5.1.2 Effects of orexin A on oxytocin release
Interestingly, among the magnocellular neurons of the PVN and SON, OX1R
immunoreactivity has been reported in oxytocin neurons (Bäckberg et al.,
2002). Aminergic neurotransmitters, including adrenaline, serotonin, and
histamine, increase oxytocin release in vitro (Gálfi et al., 2005; Kapoor and
Sladek, 2000; Radács et al., 2006) and preincubation with orexin A or orexin B
reduce these monoamine-induced increases in oxytocin levels in rat neurohy-
pophyseal tissue cultures (Ocskó et al., 2012). However, if the administration
of the monoaminergic compound precedes the orexin application, neither
orexin A nor orexin B induce changes in oxytocin release (Ocskó et al., 2012).
These findings suggest that the orexin system is intricately involved with
oxytocin secretion in the neurohypophysis and might further play a role in
the pathogenetic development of metabolic diseases by reducing the effects
of increased, monoamine-mediated oxytocin secretion (Ocskó et al., 2012;
Vacher et al., 2002). Interactions of orexins and oxytocin on hypothalamic
and neurohypophyseal as well as peripheral levels are in need of further
investigation, particularly in the in vivo situation.
5.2 Therapeutic considerations
Conventional treatment of obesity focuses on tackling abdominal fat, hyper-
tension, hyperglycemia, and dyslipidemia to reduce the risk of subsequent
diseases. Obesity prevention strategies so far include a behavioral therapeutic
approach fostering lifestyle and dietary changes. The supplementary use of
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pharmaceutical compounds with appetite suppressant activity (anorectics)
and antinutritive substances additional to lifestyle change may be further
useful for patients who have been unsuccessful with diet and exercise alone
(Apovian et al., 2015; Kaur, 2014). The US Food and Drug Administration
(FDA) has approved five weight loss drugs (orlistat, lorcaserin, naltrexone-
bupropion, phentermine-topiramate, and liraglutide) for long-term use in
obese or overweight individuals (Khera et al., 2016; Yanovski and Yanovski,
2014), achieving only modest efficacy of 5 to 10 % weight loss at 52 weeks
(Hainer, 2011; Halpern and Halpern, 2015; Khera et al., 2016; Miras and
le Roux, 2014). After achieved weight loss in obese patients, moreover, multi-
ple compensatory hormonal mechanisms encouraging weight gain, such as
decreased concentrations of leptin and insulin as well as increased ghrelin
levels, persist for at least one year and must be overcome in order to maintain
weight loss (Sumithran et al., 2011).
Beyond this background, enhancing central nervous neuropeptidergic
signaling via intranasal administration might be a promising and advantageous
strategy to improve metabolic function in the clinical setting (Chapman et al.,
2013; Spetter and Hallschmid, 2015). Key advantages are the relative safety
of peptide delivery via IN route, the high efficacy in directly targeting the
brain and patient’s higher compliance compared to conventional methods
of parenteral administration. Although there are still unanswered questions
regarding the mechanisms of intranasal neuropeptide administration, the
administration of IN insulin, orexin A, and oxytocin does not provoke any
severe treatment side effects, if any are reported at all (Baier et al., 2011;
MacDonald et al., 2011; Shemesh et al., 2012).
5.2.1 Potential of oxytocin in different clinical contexts
Due to oxytocin’s significant involvement in the regulation of social cognition
and behavior, an increasing body of evidence suggests that altered oxytocin
signaling seems to play a pathophysiological role in mental and developmen-
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tal disorders characterized by social dysfunction, such as autism spectrum
disorders (ASD), borderline personality disorder (BPD), schizophrenia, and
social anxiety disorder (SAD) (Hofmann et al., 2015; Meyer-Lindenberg
et al., 2011; Romano et al., 2016). Initial clinical studies revealed promising
results—IN oxytocin promoted emotion recognition, face processing, and
eye contact in youth with ASD (Andari et al., 2010; Auyeung et al., 2015;
Domes et al., 2013; Guastella et al., 2010), although evidence is missing for a
sustainable effect on clinical measures. An abundance of experiments exam-
ining oxytocin’s therapeutic potential in BPD, SAD, and schizophrenia led to
partially diverging results (Hofmann et al., 2015; Kirsch, 2015), suggesting
that IN oxytocin administration shows clinical potential in psychiatric disor-
ders, however, more studies are needed to determine the treatment indication
and specific symptom targets (Hofmann et al., 2015). In contrast, oxytocin’s
contribution to the regulation of food intake received much less attention than
its role in psychosocial behavior (Spetter and Hallschmid, 2017). Animal
experiments have shown that oxytocin administration inhibits ingestive behav-
ior in normal-weight rodents (Iwasaki et al., 2015) as well as in genetically
obese (Altirriba et al., 2014; Iwasaki et al., 2015) and DIO rodents (Deblon
et al., 2011; Maejima et al., 2011; Zhang et al., 2013), suggesting that oxy-
tocin treatment could bypass insulin and leptin resistance, which may occur
in association with obesity (Schwartz et al., 2000). A clinical pilot study
revealed that 8-week long-term administration of IN oxytocin reduced BMI
levels by 3.26±1.9kg/m2 and decreased waist and hip circumference in a
small sample of obese participants (Zhang et al., 2013). Although the results
of the latter study should be interpreted with caution due to different initial
conditions in the treatment and the control group regarding BMI (36 kg/m2
in the oxytocin group vs. 30 kg/m2 in the placebo group) and age (41.3 vs.
29.3 years), increased body weight seems to be a promising target of clinical
interventions. Assuming that the acute oxytocin-induced reduction in food
intake observed in Study I is equivalent over three meals per day and sustained
over time, obese patients might lose more than 21 kg body weight within one
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year, which supports the possibility using IN oxytocin as a future adjunctive
anti-obesity medication combined with behavioral therapeutic programmes.
5.2.2 Insulin as an enhancer of cognition and metabolism
Intranasal insulin has been shown to improve memory function in patients with
amnestic mild cognitive impairments and early Alzheimer’s disease (Craft
et al., 2012; Reger et al., 2008a,b) and older adults with type 2 diabetes, which
is also associated with cognitive decline (Novak et al., 2014). These results
suggest that intranasal insulin might be a promising therapeutic intervention in
the treatment as well as in the prevention of Alzheimer’s disease. Regarding to
metabolic function, IN insulin has been considered as a potential therapeutic
agent in the treatment of obesity and metabolic syndrome. Acute and chronic
intranasal insulin administration exerts anorexigenic effects (Benedict et al.,
2008; Hallschmid et al., 2004a, 2012), and increases postprandial thermogen-
esis and energy expenditure (Benedict et al., 2011). The dampening effect of
chronic IN insulin on HPA axis activity in obese (Hallschmid et al., 2008),
as well as the beneficial effect of acute IN insulin administration during the
response to social challenges like the Trier Social Stress Test (Böhringer et al.,
2008), could further normalize stress-induced chronic HPA axis overactivation
associated with the pathophysiology of obesity and cognitive decline. Our
findings from Study II extend the existing literature and may augur well for
therapeutic application in patients with deteriorations in endocrine functions
such as hypercortisolism.
5.2.3 Orexin A: Therapeutic implications beyond
narcolepsy
To date, experiments with IN orexin A administration in humans have exclu-
sively focused on narcolepsy, a neurodegenerative disease caused by loss of
CNS orexin A signaling (De la Herrán-Arita et al., 2011) leading to intermit-
tent, uncontrollable episodes of falling asleep during the daytime. Orexin A
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shows a stabilizing effect on REM sleep and reduces direct wake-to-REM tran-
sitions in narcoleptic patients when IN administered before night sleep (Baier
et al., 2011; Weinhold et al., 2014) and also improves olfactory dysfunction,
another well-known aspect of narcolepsy (Baier et al., 2008). It is noteworthy
to mention that the orexin receptor antagonist suvorexant (Belsomra®) is
applied in the treatment of chronic insomnia (Norman and Anderson, 2016).
The beneficial effects of orexin A on glucose homeostasis has been shown
in several animal studies (Ducroc et al., 2007; Sakurai, 2014a; Shiuchi et al.,
2009; Tsuneki et al., 2012) but this remains to be further investigated in
humans. However, our results from Study III suggest the orexin system as
another potential target of diabetes therapy.
5.3 Limitations and concluding remarks
Considering the broad possible therapeutic applications, the future for in-
tranasal administration of naturally occuring peptides looks bright. The
intranasal pathway for drugs to reach the CNS offers a feasible, non-invasive,
and favorable approach for achieving a good therapeutic effect with reduced
or even without systemic side effects. However, future studies need to fi-
nally answer new questions that emerge on the background of the presented
data and have to overcome a few (methodological) obstacles concerning IN
administration and some of these are discussed below.
Intranasal drug delivery is influenced by the compound’s physicochemical
properties, i.e., stability (Lai and Topp, 1999), lipophilicity (Waterhouse,
2003), and molecular weight (Pardridge, 2002) which essentially determines
absorption rate and bioavailability. There seems to be less control over dosing
with intranasal delivery of high-molecular-weight drugs, e.g., neuropeptides,
compared with parenteral and oral routes due to differing absorption rates
and delivery pathways within the nasal epithelium (see section 1.4; Dhuria
et al., 2010). Moreover, the amount of absorbed peptide molecules in relative
contribution to the net uptake may differ interindividually due to anatomic
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variabilities of the nasal cavity in size and volume (Samolin´ski et al., 2007).
Suitable strategies in order to enhance the delivery of macromolecules from
the nasal cavity to CNS should be developed and implemented in future
studies. For instance, animal studies indicated that the brain specificity of the
IN route for insulin may be improved via coadministration of cell-penetrating
peptides that facilitate cellular uptake of the peptide and may reduce the level
of systemic insulin exposure (Kamei and Takeda-Morishita, 2015). Other
emerging peptide technologies like multifunctional peptides (Fosgerau and
Hoffmann, 2015) or the use of long-lasting peptide analogs (Benedict et al.,
2007; Mizuno et al., 2015) might also help increasing efficacy and broadening
the therapeutic applicability. To further reduce variability in the response to
nasal sprays between experiments and individuals, a standardization of IN
administration and guidelines for its reporting in human research is strongly
recommended (Guastella et al., 2013).
Another aspect to be addressed in the future are long-term effects and side
effects of intranasal administration of neuropeptides. While a single dose of
oxytocin, insulin, and orexin A is undoubtedly safe, there is sparse empirical
evidence about repeated administration over a longer time period. Subchronic
IN administration of insulin (Benedict et al., 2005, 2007) and oxytocin over
8 weeks (Muin et al., 2015; Zhang et al., 2013) and even a 4-month daily
treatment with IN oxytocin in schizophrenic patients (Busnelli et al., 2016)
does not exert severe side effects or other medical complications. However,
studies in vitro showed that sustained exposure of hypothalamic cells to high
concentrations of insulin diminishes central insulin signaling via inactivation
and degradation of the insulin receptor and insulin receptor substrate-1 (Mayer
and Belsham, 2010). Thus, dosage and duration of IN insulin administration
in a clinical setting has to be considered very critically. Regarding oxytocin,
some studies in humans revealed a ‘dark side’ of the peptide by increasing in-
group coherence at the expense of intergroup affiliation (De Dreu et al., 2011;
Shalvi and De Dreu, 2014) or hindering cooperative behavior in BPD after
IN administration of oxytocin (Bartz et al., 2011). Moreover, experiments
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on chronic IN oxytocin administration in rodents point to possible aversive
effects on social and partner preference behavior (Bales et al., 2013; Huang
et al., 2014). Such psychosocial outcomes should be carefully addressed in
therapeutic contexts. It is also noteworthy that SC oxytocin treatment of obese
diabetic mice for 2 weeks dose-dependently prevented further body weight
gain which was surprisingly accompanied by worsened basal glycemia and
glucose tolerance (Altirriba et al., 2014). Results like these call for the careful
selection of the experimental or therapeutic conditions in which oxytocin
treatment can be expected to act beneficially on obesity and its comorbidities.
In sum, the results in the present thesis seem promising for IN adminis-
tration of insulin, oxytocin, and orexin A in a clinical setting, where it may
support conventional treatment approaches in obesity and metabolic disorders.
Considering that data on long-term therapeutic and side effects of IN admin-
istration of these as well as other peptides in humans are still limited, much
more empirical work is necessary to fully grasp the potential of IN peptide
delivery in patients. With over 700 registered clinical trials worldwide in-
vestigating intranasal administration (clinicaltrials.gov), this rapidly growing
method of administration is on the way up.
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